insert into openchpl.practice_type (name, description, last_modified_user) values ('Ambulatory', 'Ambulatory', -1), ('Inpatient', 'Inpatient', -1);
insert into openchpl.product_classification_type (name, description, last_modified_user) values ('Modular EHR', 'Modular EHR', -1), ('Complete EHR', 'Complete EHR', -1);
insert into openchpl.certification_edition (year, retired, last_modified_user) values (2011, true, -1), (2014, false, -1), (2015, false, -1);
insert into openchpl.cqm_criterion_type (name, description, last_modified_user) values ('Ambulatory', 'Ambulatory', -1), ('Inpatient','Inpatient',-1);
insert into openchpl.event_type (name, description, last_modified_user) values ('Certification','Product is certified', -1), ('Active', 'Product moved from Pending to Active', -1);
insert into openchpl.cqm_version (version, last_modified_user) values ('v0', -1), ('v1', -1), ('v2', -1), ('v3', -1), ('v4', -1), ('v5', -1), ('v6', -1);
insert into openchpl.certification_status (certification_status, last_modified_user) values ('Active', -1), ('Retired', -1), ('Withdrawn by Developer', -1), ('Withdrawn by ONC-ACB', -1), ('Pending', -1), ('Suspended by ONC-ACB', -1), ('Suspended by ONC', -1), ('Terminated by ONC', -1);
insert into openchpl.education_type (name, last_modified_user) values ('No high school degree', -1), ('High school graduate, diploma or the equivalent (for example: GED)', -1), ('Some college credit, no degree', -1), ('Trade/technical/vocational training', -1), ('Associate degree', -1), ('Bachelor''s degree', -1), ('Master''s degree', -1), ('Doctorate degree (e.g., MD, DNP, DMD, PhD)', -1);
insert into openchpl.test_participant_age (age, last_modified_user) values ('0-9', -1),('10-19', -1),('20-29', -1),('30-39', -1),('40-49', -1),('50-59', -1),('60-69', -1),('70-79', -1),('80-89', -1),('90-99', -1),('100+', -1);
insert into openchpl.vendor_status (name, last_modified_user) values('Active', -1), ('Suspended by ONC', -1), ('Under certification ban by ONC', -1);

INSERT INTO openchpl.surveillance_type (name, last_modified_user)
values ('Reactive', -1),('Randomized', -1);

INSERT INTO openchpl.surveillance_requirement_type (name, last_modified_user)
values ('Certified Capability', -1), ('Transparency or Disclosure Requirement', -1),
('Other Requirement', -1);

INSERT INTO openchpl.surveillance_result (name, last_modified_user)
values ('Non-Conformity', -1), ('No Non-Conformity', -1);

INSERT INTO openchpl.nonconformity_status (name, last_modified_user)
values ('Open', -1), ('Closed', -1);

INSERT INTO openchpl.certification_criterion (certification_edition_id, number, title, last_modified_user) VALUES
(3, '170.315 (a)(1)', 'Computerized Provider Order Entry (CPOE) - Medications', -1),
(3, '170.315 (a)(2)', 'CPOE - Laboratory', -1),
(3, '170.315 (a)(3)', 'CPOE - Diagnostic Imaging', -1),
(3, '170.315 (a)(4)', 'Drug-Drug, Drug-Allergy Interaction Checks for CPOE', -1),
(3, '170.315 (a)(5)', 'Demographics', -1),
(3, '170.315 (a)(6)', 'Problem List', -1),
(3, '170.315 (a)(7)', 'Medication List', -1),
(3, '170.315 (a)(8)', 'Medication Allergy List', -1),
(3, '170.315 (a)(9)', 'Clinical Decision Support', -1),
(3, '170.315 (a)(10)', 'Drug-Formulary and Preferred Drug List Checks', -1),
(3, '170.315 (a)(11)', 'Smoking Status', -1),
(3, '170.315 (a)(12)', 'Family Health History', -1),
(3, '170.315 (a)(13)', 'Patient-Specific Education Resources', -1),
(3, '170.315 (a)(14)', 'Implantable Device List', -1),
(3, '170.315 (a)(15)', 'Social, Psychological, and Behavioral Determinants Data', -1),
(3, '170.315 (b)(1)', 'Transitions of Care', -1),
(3, '170.315 (b)(2)', 'Clinical Information Reconciliation and Incorporation', -1),
(3, '170.315 (b)(3)', 'Electronic Prescribing', -1),
(3, '170.315 (b)(4)', 'Common Clinical Data Set Summary Record - Create', -1),
(3, '170.315 (b)(5)', 'Common Clinical Data Set Summary Record - Receive', -1),
(3, '170.315 (b)(6)', 'Data Export', -1),
(3, '170.315 (b)(7)', 'Data Segmentation for Privacy - Send', -1),
(3, '170.315 (b)(8)', 'Data Segmentation for Privacy - Receive', -1),
(3, '170.315 (b)(9)', 'Care Plan', -1),
(3, '170.315 (c)(1)', 'Clinical Quality Measures - Record and Export', -1),
(3, '170.315 (c)(2)', 'Clinical Quality Measures - Import and Calculate', -1),
(3, '170.315 (c)(3)', 'Clinical Quality Measures - Report', -1),
(3, '170.315 (c)(4)', 'Clinical Quality Measures - Filter', -1),
(3, '170.315 (d)(1)', 'Authentication, Access Control, Authorization', -1),
(3, '170.315 (d)(2)', 'Auditable Events and Tamper-Resistance', -1),
(3, '170.315 (d)(3)', 'Audit Report(s)', -1),
(3, '170.315 (d)(4)', 'Amendments', -1),
(3, '170.315 (d)(5)', 'Automatic Access Time-out', -1),
(3, '170.315 (d)(6)', 'Emergency Access', -1),
(3, '170.315 (d)(7)', 'End-User Device Encryption', -1),
(3, '170.315 (d)(8)', 'Integrity', -1),
(3, '170.315 (d)(9)', 'Trusted Connection', -1),
(3, '170.315 (d)(10)', 'Auditing Actions on Health Information', -1),
(3, '170.315 (d)(11)', 'Accounting of Disclosures', -1),
(3, '170.315 (e)(1)', 'View, Download, and Transmit to 3rd Party', -1),
(3, '170.315 (e)(2)', 'Secure Messaging', -1),
(3, '170.315 (e)(3)', 'Patient Health Information Capture', -1),
(3, '170.315 (f)(1)', 'Transmission to Immunization Registries', -1),
(3, '170.315 (f)(2)', 'Transmission to Public Health Agencies - Syndromic Surveillance', -1),
(3, '170.315 (f)(3)', 'Transmission to Public Health Agencies - Reportable Laboratory Tests and Values/Results', -1),
(3, '170.315 (f)(4)', 'Transmission to Cancer Registries', -1),
(3, '170.315 (f)(5)', 'Transmission to Public Health Agencies - Electronic Case Reporting', -1),
(3, '170.315 (f)(6)', 'Transmission to Public Health Agencies - Antimicrobial Use and Resistance Reporting', -1),
(3, '170.315 (f)(7)', 'Transmission to Public Health Agencies - Health Care Surveys', -1),
(3, '170.315 (g)(1)', 'Automated Numerator Recording', -1),
(3, '170.315 (g)(2)', 'Automated Measure Calculation', -1),
(3, '170.315 (g)(3)', 'Safety-Enhanced Design', -1),
(3, '170.315 (g)(4)', 'Quality Management System', -1),
(3, '170.315 (g)(5)', 'Accessibility-Centered Design', -1),
(3, '170.315 (g)(6)', 'Consolidated CDA Creation', -1),
(3, '170.315 (g)(7)', 'Application Access - Patient Selection', -1),
(3, '170.315 (g)(8)', 'Application Access - Data Category Request', -1),
(3, '170.315 (g)(9)', 'Application Access - All Data Request', -1),
(3, '170.315 (h)(1)', 'Direct Project', -1),
(3, '170.315 (h)(2)', 'Direct Project, Edge Protocol, and XDR/XDM', -1),
(2, '170.314 (a)(1)', 'Computerized provider order entry', -1),
(2, '170.314 (a)(2)', 'Drug-drug, drug-allergy interactions checks', -1),
(2, '170.314 (a)(3)', 'Demographics', -1),
(2, '170.314 (a)(4)', 'Vital signs, body mass index, and growth Charts', -1),
(2, '170.314 (a)(5)', 'Problem list', -1),
(2, '170.314 (a)(6)', 'Medication list', -1),
(2, '170.314 (a)(7)', 'Medication allergy list', -1),
(2, '170.314 (a)(8)', 'Clinical decision support', -1),
(2, '170.314 (a)(9)', 'Electronic notes', -1),
(2, '170.314 (a)(10)', 'Drug formulary checks', -1),
(2, '170.314 (a)(11)', 'Smoking status', -1),
(2, '170.314 (a)(12)', 'Image results', -1),
(2, '170.314 (a)(13)', 'Family health history', -1),
(2, '170.314 (a)(14)', 'Patient list creation', -1),
(2, '170.314 (a)(15)', 'Patient-specific education resources', -1),
(2, '170.314 (a)(16)', 'Inpatient setting only - electronic medication administration record', -1),
(2, '170.314 (a)(17)', 'Advance directives', -1),
(2, '170.314 (a)(18)', 'Optional - computerized provider order entry - medications', -1),
(2, '170.314 (a)(19)', 'Optional - computerized provider order entry - laboratory', -1),
(2, '170.314 (a)(20)', 'Optional - computerized provider order entry - diagnostic imaging', -1),
(2, '170.314 (b)(1)', 'Transitions of care - receive, display and incorporate transition of care/referral summaries', -1),
(2, '170.314 (b)(2)', 'Transitions of care - create and transmit transition of care/referral summaries', -1),
(2, '170.314 (b)(3)', 'Electronic prescribing', -1),
(2, '170.314 (b)(4)', 'Clinical information reconciliation', -1),
(2, '170.314 (b)(5)(A)', 'Incorporate laboratory tests and values/results', -1),
(2, '170.314 (b)(5)(B)', 'Incorporate laboratory tests and values/results', -1),
(2, '170.314 (b)(6)', 'Inpatient setting only - transmission of electronic laboratory tests and values/results to ambulatory providers', -1),
(2, '170.314 (b)(7)', 'Data portability', -1),
(2, '170.314 (b)(8)', 'Optional - transitions of care', -1),
(2, '170.314 (b)(9)', 'Optional - clinical information reconciliation and incorporation (CIRI)', -1),
(2, '170.314 (c)(1)', 'Clinical quality measures - capture and export', -1),
(2, '170.314 (c)(2)', 'Clinical quality measures - import and calculate', -1),
(2, '170.314 (c)(3)', 'Clinical quality measures - electronic submission', -1),
(2, '170.314 (d)(1)', 'Authentication, access, control, and authorization', -1),
(2, '170.314 (d)(2)', 'Auditable events and tamper-resistance', -1),
(2, '170.314 (d)(3)', 'Audit report(s)', -1),
(2, '170.314 (d)(4)', 'Amendments', -1),
(2, '170.314 (d)(5)', 'Automatic log-off', -1),
(2, '170.314 (d)(6)', 'Emergency access', -1),
(2, '170.314 (d)(7)', 'End-user device encryption', -1),
(2, '170.314 (d)(8)', 'Integrity', -1),
(2, '170.314 (d)(9)', 'Optional - accounting of disclosures', -1),
(2, '170.314 (e)(1)', 'View, download, and transmit to a 3rd party with edge protocol testing', -1),
(2, '170.314 (e)(2)', 'Ambulatory setting only -clinical summary', -1),
(2, '170.314 (e)(3)', 'Ambulatory setting only - secure messaging', -1),
(2, '170.314 (f)(1)', 'Immunization information', -1),
(2, '170.314 (f)(2)', 'Transmission to immunization registries', -1),
(2, '170.314 (f)(3)', 'Transmission to public health agencies - syndromic surveillance', -1),
(2, '170.314 (f)(4)', 'Inpatient setting only - transmission of reportable laboratory tests and values/results', -1),
(2, '170.314 (f)(5)', 'Optional - ambulatory setting only - cancer case information', -1),
(2, '170.314 (f)(6)', 'Optional - ambulatory setting only - transmission to cancer registries', -1),
(2, '170.314 (f)(7)', 'Optional - ambulatory setting only - transmission to public health agencies - syndromic surveillance', -1),
(2, '170.314 (g)(1)', 'Automated numerator recording', -1),
(2, '170.314 (g)(2)', 'Automated measure calculation', -1),
(2, '170.314 (g)(3)', 'Safety-enhanced design', -1),
(2, '170.314 (g)(4)', 'Quality management system', -1),
(2, '170.314 (h)(1)', 'Optional - Transmit - Applicability Statement for Secure Health', -1),
(2, '170.314 (h)(2)', 'Optional - Transmit - Applicability Statement for Secure Health Transport and XDR/XDM for Direct Messaging', -1),
(2, '170.314 (h)(3)', 'Optional - Transmit - SOAP Transport and Security Specification and XDR/XDM for Direct Messaging', -1),
(1, '170.302 (a)', 'Drug-drug, drug-allergy interaction checks', -1),
(1, '170.302 (b)', 'Drug formulary checks', -1),
(1, '170.302 (c)', 'Maintain up-to-date problem list', -1),
(1, '170.302 (d)', 'Maintain active medication list', -1),
(1, '170.302 (e)', 'Maintain active medication allergy list', -1),
(1, '170.302 (f)(1)', 'Vital signs', -1),
(1, '170.302 (f)(2)', 'Calculate body mass index', -1),
(1, '170.302 (f)(3)', 'Plot and display growth charts', -1),
(1, '170.302 (g)', 'Smoking status', -1),
(1, '170.302 (h)', 'Incorporate laboratory test results', -1),
(1, '170.302 (i)', 'Generate patient lists', -1),
(1, '170.302 (j)', 'Medication reconciliation', -1),
(1, '170.302 (k)', 'Submission to immunization registries', -1),
(1, '170.302 (l)', 'Public health surveillance', -1),
(1, '170.302 (m)', 'Patient specific education resources', -1),
(1, '170.302 (n)', 'Automated measure calculation', -1),
(1, '170.302 (o)', 'Access control', -1),
(1, '170.302 (p)', 'Emergency access', -1),
(1, '170.302 (q)', 'Automatic log-off', -1),
(1, '170.302 (r)', 'Audit log', -1),
(1, '170.302 (s)', 'Integrity', -1),
(1, '170.302 (t)', 'Authentication', -1),
(1, '170.302 (u)', 'General encryption', -1),
(1, '170.302 (v)', 'Encryption when exchanging electronic health information', -1),
(1, '170.302 (w)', 'Accounting of disclosures (optional)', -1),
(1, '170.304 (a)', 'Computerized provider order entry', -1),
(1, '170.304 (b)', 'Electronic Prescribing', -1),
(1, '170.304 (c)', 'Record demographics', -1),
(1, '170.304 (d)', 'Patient reminders', -1),
(1, '170.304 (e)', 'Clinical decision support', -1),
(1, '170.304 (f)', 'Electronic copy of health information', -1),
(1, '170.304 (g)', 'Timely access', -1),
(1, '170.304 (h)', 'Clinical summaries', -1),
(1, '170.304 (i)', 'Exchange clinical information and patient summary record', -1),
(1, '170.304 (j)', 'Calculate and submit clinical quality measures', -1),
(1, '170.306 (a)', 'Computerized provider order entry', -1),
(1, '170.306 (b)', 'Record demographics', -1),
(1, '170.306 (c)', 'Clinical decision support', -1),
(1, '170.306 (d)(1)', 'Electronic copy of health information', -1),
(1, '170.306 (d)(2)', 'Electronic copy of health information', -1),
(1, '170.306 (e)', 'Electronic copy of discharge instructions', -1),
(1, '170.306 (f)', 'Exchange clinical information and patient summary record', -1),
(1, '170.306 (g)', 'Reportable lab results', -1),
(1, '170.306 (h)', 'Advance directives', -1),
(1, '170.306 (i)', 'Calculate and submit clinical quality measures', -1);

INSERT INTO openchpl.cqm_criterion (title, nqf_number, description, cqm_criterion_type_id, last_modified_user, retired) VALUES
('Asthma Assessment', '0001', 'Percentage of patients aged 5 through 40 years with a diagnosis of asthma and who have been seen for at least 2 office visits, which were evaluated during at least one office visit within 12 months for the frequency (numeric) of daytime and nocturnal asthma symptoms.', 1, -1, true),
('Appropriate Testing for Children with Pharyngitis', '0002', 'Percentage of children 2-18 years of age, who were diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode', 1, -1, true),
('Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: a) Initiation, b) Engagement', '0004', 'Percentage of adolescent and adult patients with a new episode of alcohol and other drug (AOD) dependence who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis and who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.', 1, -1, true),
('Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)', '0012', 'Percentage of patients, regardless of age, who gave birth during a 12-month period who were screened for HIV infection during the first or second prenatal care visit.', 1, -1, true),
('Hypertension: Blood Pressure Measurement', '0013', 'Percentage of patient visits for patients aged 18 years and older with a diagnosis of hypertension who has been seen for at least 2 office visits, with blood pressure (BP) recorded.', 1, -1, true),
('Prenatal Care: Anti-D Immune Globulin', '0014', 'Percentage of D(Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12-month period who received anti-D immune globulin at 26-30 weeks gestation.', 1, -1, true),
('Controlling High Blood Pressure', '0018', 'The percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose BP was adequately controlled during the measurement year.', 1, -1, true),
('Weight Assessment and Counseling for Children and Adolescents', '0024', 'The percentage of patients 2 -17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or OB/GYN and who had evidence of BMI percentile documentation, counseling for nutrition and counseling for physical activity during the measurement year.', 1, -1, true),
('Smoking and Tobacco Use Cessation, Medical assistance: a) Advising Smokers and Tobacco Users to Quit, b) Discussing Smoking and Tobacco Use Cessation Medications, c) Discussing Smoking and Tobacco Use Cessation Strategies', '0027', 'Percentage of patients 18 years of age and older who were current smokers or tobacco users, who were seen by a practitioner during the measurement year and who received advice to quit smoking or tobacco use or whose practitioner recommended or discussed smoking or tobacco use cessation medications, methods or strategies.', 1, -1, true),
('Preventive Care and Screening Measure Pair: a) Tobacco Use Assessment b) Tobacco Cessation Intervention', '0028', 'a) Tobacco Use Assessment. Description: Percentage of patients aged 18 years and older who have been seen for at least 2 office visits who were queried about tobacco use one or more times within 24 months. b) Tobacco Cessation Intervention Description: Percentage of patients aged 18 years and older identified as tobacco users within the past 24 months and have been seen for at least 2 office visits, who received cessation intervention', 1, -1, true),
('Breast Cancer Screening', '0031', 'Percentage of women 40-69 years of age who had a mammogram to screen for breast cancer.', 1, -1, true),
('Cervical Cancer Screening', '0032', 'The percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose BP was adequately controlled during the measurement year', 1, -1, true),
('Chlamydia Screening for Women', '0033', 'Percentage of women 15- 24 years of age who were identified as sexually active and who had at least one test for Chlamydia during the measurement year.', 1, -1, true),
('Colorectal Cancer Screening', '0034', 'Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer.', 1, -1, true),
('Use of Appropriate Medications for Asthma', '0036', 'Percentage of patients 5-50 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement year. Report three age stratifications (5-11 years, 12-50 years, and total).', 1, -1, true),
('Childhood Immunization Status', '0038', 'Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); two H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); two hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and two separate combination rates.', 1, -1, true),
('Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old', '0041', 'Percentage of patients aged 50 years and older who received an influenza immunization during the flu season (September through February).', 1, -1, true),
('Pneumonia Vaccination Status for Older Adults', '0043', 'Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.', 1, -1, true),
('Asthma Pharmacologic Therapy', '0047', 'Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment.', 1, -1, true),
('Low Back Pain: Use of Imaging Studies', '0052', 'Percentage of patients with a primary diagnosis of low back pain who did not have an imaging study (plain x-ray, MRI, CT scan) within 28 days of diagnosis.', 1, -1, true),
('Diabetes: Eye Exam', '0055', 'Percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had a retinal or dilated eye exam or a negative retinal exam (no evidence of retinopathy) by an eye care professional.', 1, -1, true),
('Diabetes: Foot Exam', '0056', 'The percentage of patients aged 18-75 years with diabetes (type 1 or type 2) who had a foot exam (visual inspection, sensory exam with monofilament, or pulse exam).', 1, -1, true),
('Diabetes: HbA1c Poor Control', '0059', 'Percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had hemoglobin A1c > 9.0%.', 1, -1, true),
('Diabetes: Blood Pressure Management', '0061', 'Percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.', 1, -1, true),
('Diabetes: Urine Screening', '0062', 'Percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had a nephropathy screening test or evidence of nephropathy.', 1, -1, true),
('Diabetes: LDL Management & Control', '0064', 'Percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL.', 1, -1, true),
('Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD', '0067', 'Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed oral antiplatelet therapy.', 1, -1, true),
('Ischemic Vascular Disease (IVD): Use of Aspirin or another Antithrombotic', '0068', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1-November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had documentation of use of aspirin or another antithrombotic during the measurement year.', 1, -1, true),
('Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)', '0070', 'Percentage of patients aged 18 years and older with a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy.', 1, -1, true),
('Ischemic Vascular Disease (IVD): Blood Pressure Management', '0073', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1-November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and whose recent blood pressure is in control (<140/90 mmHg).', 1, -1, true),
('Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL- Cholesterol', '0074', 'Percentage of patients aged 18 years and older with a diagnosis of CAD who was prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines).', 1, -1, true),
('Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control', '0075', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal angioplasty (PTCA) from January 1-November1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had a complete lipid profile performed during the measurement year and whose LDL-C<100 mg/dL.', 1, -1, true),
('Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0081', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure and LVSD (LVEF < 40%) who were prescribed ACE inhibitor or ARB therapy.', 1, -1, true),
('Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0083', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were prescribed beta-blocker therapy', 1, -1, true),
('Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation', '0084', 'Percentage of all patients aged 18 years and older with a diagnosis of heart failure and paroxysmal or chronic atrial fibrillation that were prescribed warfarin therapy.', 1, -1, true),
('Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation', '0086', 'Percentage of patients aged 18 years and older with a diagnosis of POAG who have been seen for at least two office visits who have an optic nerve head evaluation during one or more office visits within 12 months.', 1, -1, true),
('Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy', '0088', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months.', 1, -1, true),
('Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care', '0089', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months.', 1, -1, true),
('Anti-depressant medication management: (a) Effective Acute Phase Treatment, (b) Effective Continuation Phase Treatment', '0105', 'Percentage of patients 18 years of age and older who were diagnosed with a new episode of major depression, treated with antidepressant medication, and who remained on an antidepressant medication treatment', 1, -1, true),
('Venous Thromboembolism (VTE)-1 VTE prophylaxis', '0371', 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.', 2, -1, true),
('VTE-2 Intensive Care Unit (ICU) VTE prophylaxis', '0372', 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).', 2, -1, true),
('VTE-3 VTE Patients with Overlap of Anticoagulation Therapy', '0373', 'This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they must be discharged on both medications. Overlap therapy must be administered for at least five days with an international normalized ratio (INR) = 2 prior to discontinuation of the parenteral anticoagulation therapy or the patient must be discharged on both medications.', 2, -1, true),
('VTE-4 VTE Patients Unfractionated Heparin (UFH) Dosages/Platelet Count Monitoring by Protocol (or Nomogram) Receiving Unfractionated Heparin (UFH) with Dosages/ Platelet Count Monitored by Protocol (or Nomogram)', '0374', 'This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.', 2, -1, true),
('VTE-5 VTE discharge instructions', '0375', 'This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, to home with home health, or home hospice on warfarin with written discharge instructions that address all four criteria: compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/interactions.', 2, -1, true),
('VTE-6 Incidence of potentially preventable VTE', '0376', 'This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present on arrival) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date.', 2, -1, true),
('Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients', '0385', 'Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12 month reporting period.', 1, -1, true),
('Oncology Breast Cancer: Hormonal Therapy for Stage IC- IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer', '0387', 'Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.', 1, -1, true),
('Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients', '0389', 'Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer.', 1, -1, true),
('Adult Weight Screening and Follow-up', '0421', 'Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the current visit documented in the medical record AND if the most recent BMI is outside parameters, a follow-up plan is documented.', 1, -1, true),
('Stroke-2 Ischemic stroke - Discharged on anti-thrombotic therapy', '0435', 'Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge.', 2, -1, true),
('Stroke-3 Ischemic stroke - Anticoagulation Therapy for Atrial Fibrillation/Flutter', '0436', 'Ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.', 2, -1, true),
('Stroke-4 Ischemic stroke - Thrombolytic Therapy', '0437', 'Acute ischemic stroke patients who arrive at this hospital within 2 hours (120 minutes) of time last known well and for whom IV t-PA was initiated at this hospital within 3 hours (180 minutes) of time last known well.', 2, -1, true),
('Stroke-5 Ischemic stroke - Antithrombotic therapy by end of hospital day two', '0438', 'Ischemic stroke patients administered antithrombotic therapy by the end of hospital day two.', 2, -1, true),
('Stroke-6 Ischemic stroke - Discharged on Statin Medication', '0439', 'Ischemic stroke patients with LDL greater than or equal to 100 mg/dL, or LDL not measured, or, who were on a lipid-lowering medication prior to hospital arrival are prescribed statin medication at hospital discharge.', 2, -1, true),
('Stroke-8 Ischemic or hemorrhagic stroke - Stroke education', '0440', 'Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for followup after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.', 2, -1, true),
('Stroke-10 Ischemic or hemorrhagic stroke - Assessed for rehabilitation', '0441', 'Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.', 2, -1, true),
('Emergency Department (ED)-1 Emergency Department Throughput - Median time from ED arrival to ED departure for admitted ED patients', '0495', 'Median time from emergency department arrival to time of departure from the emergency room for patients admitted to the facility from the emergency department.', 2, -1, true),
('ED-2 Emergency Department Throughput - Admitted patients - Admit decision time to ED departure time for admitted patients', '0497', 'Median time from admit decision time to time of departure from the emergency department for emergency department patients admitted to inpatient status.', 2, -1, true),
('Diabetes: HbA1c Control (<8%)', '0575', 'The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had HbA1c <8.0%.', 1, -1, true);

INSERT INTO openchpl.cqm_criterion (cms_id, cqm_version_id, title, nqf_number, number, description, cqm_domain, cqm_criterion_type_id, last_modified_user, retired) VALUES
('CMS82', 1, 'Maternal Depression Screening', 'N/A', '372', 'The percentage of children who turned 6 months of age during the measurement year, who had a face-to-face visit between the clinician and the child during child''s first 6 months, and who had a maternal depression screening for the mother at least once between 0 and 6 months of life', 'Population/Public Health.', 1, -1, false),
('CMS82', 2, 'Maternal Depression Screening', 'N/A', '372', 'The percentage of children who turned 6 months of age during the measurement year, who had a face-to-face visit between the clinician and the child during child''s first 6 months, and who had a maternal depression screening for the mother at least once between 0 and 6 months of life', 'Population/Public Health.', 1, -1, false),
('CMS82', 3, 'Maternal Depression Screening', 'N/A', '372', 'The percentage of children who turned 6 months of age during the measurement year, who had a face-to-face visit between the clinician and the child during child''s first 6 months, and who had a maternal depression screening for the mother at least once between 0 and 6 months of life', 'Population/Public Health.', 1, -1, false),
('CMS82', 4, 'Maternal Depression Screening', 'N/A', '372', 'The percentage of children who turned 6 months of age during the measurement year, who had a face-to-face visit between the clinician and the child during child''s first 6 months, and who had a maternal depression screening for the mother at least once between 0 and 6 months of life', 'Population/Public Health.', 1, -1, false),
('CMS26', 1, 'Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver', 'N/A', null, 'An assessment that there is documentation in the medical record that a Home Management Plan of Care (HMPC) document was given to the pediatric asthma patient/caregiver.', 'Patient and Family Engagement', 2, -1, false),
('CMS26', 2, 'Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver', 'N/A', null, 'An assessment that there is documentation in the medical record that a Home Management Plan of Care (HMPC) document was given to the pediatric asthma patient/caregiver.', 'Patient and Family Engagement', 2, -1, false),
('CMS26', 3, 'Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver', 'N/A', null, 'An assessment that there is documentation in the medical record that a Home Management Plan of Care (HMPC) document was given to the pediatric asthma patient/caregiver.', 'Patient and Family Engagement', 2, -1, false),
('CMS26', 4, 'Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver', 'N/A', null, 'An assessment that there is documentation in the medical record that a Home Management Plan of Care (HMPC) document was given to the pediatric asthma patient/caregiver.', 'Patient and Family Engagement', 2, -1, false),
('CMS146', 1, 'Appropriate Testing for Children with Pharyngitis', '0002', '066', 'Percentage of children 2-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode.', 'Efficient Use of Healthcare Resources', 1, -1, false),
('CMS146', 2, 'Appropriate Testing for Children with Pharyngitis', '0002', '066', 'Percentage of children 2-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode.', 'Efficient Use of Healthcare Resources', 1, -1, false),
('CMS146', 3, 'Appropriate Testing for Children with Pharyngitis', '0002', '066', 'Percentage of children 2-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode.', 'Efficient Use of Healthcare Resources', 1, -1, false),
('CMS146', 4, 'Appropriate Testing for Children with Pharyngitis', '0002', '066', 'Percentage of children 2-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode.', 'Efficient Use of Healthcare Resources', 1, -1, false),
('CMS146', 5, 'Appropriate Testing for Children with Pharyngitis', '0002', '066', 'Percentage of children 2-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode.', 'Efficient Use of Healthcare Resources', 1, -1, false),
('CMS137', 1, 'Initiation and Engagement of Alcohol and Other Drug Dependence Treatment', '0004', '305', 'Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported.  Percentage of patients who initiated treatment within 14 days of the diagnosis.  Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS137', 2, 'Initiation and Engagement of Alcohol and Other Drug Dependence Treatment', '0004', '305', 'Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported.  Percentage of patients who initiated treatment within 14 days of the diagnosis.  Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS137', 3, 'Initiation and Engagement of Alcohol and Other Drug Dependence Treatment', '0004', '305', 'Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported.  Percentage of patients who initiated treatment within 14 days of the diagnosis.  Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS137', 4, 'Initiation and Engagement of Alcohol and Other Drug Dependence Treatment', '0004', '305', 'Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported.  Percentage of patients who initiated treatment within 14 days of the diagnosis.  Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS137', 5, 'Initiation and Engagement of Alcohol and Other Drug Dependence Treatment', '0004', '305', 'Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported.  Percentage of patients who initiated treatment within 14 days of the diagnosis.  Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS165', 1, 'Controlling High Blood Pressure', '0018', '236 GPRO HTN-2', 'Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS165', 2, 'Controlling High Blood Pressure', '0018', '236 GPRO HTN-2', 'Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS165', 3, 'Controlling High Blood Pressure', '0018', '236 GPRO HTN-2', 'Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS165', 4, 'Controlling High Blood Pressure', '0018', '236 GPRO HTN-2', 'Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS165', 5, 'Controlling High Blood Pressure', '0018', '236 GPRO HTN-2', 'Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS156', 1, 'Use of High-Risk Medications in the Elderly', '0022', '238', 'Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported.  Percentage of patients who were ordered at least one high-risk medication.  Percentage of patients who were ordered at least two different high-risk medications.', 'Patient Safety.', 1, -1, false),
('CMS156', 2, 'Use of High-Risk Medications in the Elderly', '0022', '238', 'Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported.  Percentage of patients who were ordered at least one high-risk medication.  Percentage of patients who were ordered at least two different high-risk medications.', 'Patient Safety.', 1, -1, false),
('CMS156', 3, 'Use of High-Risk Medications in the Elderly', '0022', '238', 'Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported.  Percentage of patients who were ordered at least one high-risk medication.  Percentage of patients who were ordered at least two different high-risk medications.', 'Patient Safety.', 1, -1, false),
('CMS156', 4, 'Use of High-Risk Medications in the Elderly', '0022', '238', 'Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported.  Percentage of patients who were ordered at least one high-risk medication.  Percentage of patients who were ordered at least two different high-risk medications.', 'Patient Safety.', 1, -1, false),
('CMS156', 5, 'Use of High-Risk Medications in the Elderly', '0022', '238', 'Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported.  Percentage of patients who were ordered at least one high-risk medication.  Percentage of patients who were ordered at least two different high-risk medications.', 'Patient Safety.', 1, -1, false),
('CMS155', 1, 'Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents', '0024', '239', 'Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are reported.  Percentage of patients with height, weight, and body mass index (BMI) percentile documentation  Percentage of patients with counseling for nutrition  Percentage of patients with counseling for physical activity', 'Population/Public Health.', 1, -1, false),
('CMS155', 2, 'Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents', '0024', '239', 'Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are reported.  Percentage of patients with height, weight, and body mass index (BMI) percentile documentation  Percentage of patients with counseling for nutrition  Percentage of patients with counseling for physical activity', 'Population/Public Health.', 1, -1, false),
('CMS155', 3, 'Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents', '0024', '239', 'Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are reported.  Percentage of patients with height, weight, and body mass index (BMI) percentile documentation  Percentage of patients with counseling for nutrition  Percentage of patients with counseling for physical activity', 'Population/Public Health.', 1, -1, false),
('CMS155', 4, 'Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents', '0024', '239', 'Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are reported.  Percentage of patients with height, weight, and body mass index (BMI) percentile documentation  Percentage of patients with counseling for nutrition  Percentage of patients with counseling for physical activity', 'Population/Public Health.', 1, -1, false),
('CMS155', 5, 'Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents', '0024', '239', 'Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are reported.  Percentage of patients with height, weight, and body mass index (BMI) percentile documentation  Percentage of patients with counseling for nutrition  Percentage of patients with counseling for physical activity', 'Population/Public Health.', 1, -1, false),
('CMS138', 1, 'Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention', '0028', '226 GPRO PREV-10', 'Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user', 'Population/Public Health.', 1, -1, false),
('CMS138', 2, 'Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention', '0028', '226 GPRO PREV-10', 'Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user', 'Population/Public Health.', 1, -1, false),
('CMS138', 3, 'Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention', '0028', '226 GPRO PREV-10', 'Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user', 'Population/Public Health.', 1, -1, false),
('CMS138', 4, 'Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention', '0028', '226 GPRO PREV-10', 'Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user', 'Population/Public Health.', 1, -1, false),
('CMS138', 5, 'Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention', '0028', '226 GPRO PREV-10', 'Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user', 'Population/Public Health.', 1, -1, false),
('CMS124', 1, 'Cervical Cancer Screening', '0032', '309', 'Percentage of women 21-64 years of age, who received one or more Pap tests to screen for cervical cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS124', 2, 'Cervical Cancer Screening', '0032', '309', 'Percentage of women 21-64 years of age, who received one or more Pap tests to screen for cervical cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS124', 3, 'Cervical Cancer Screening', '0032', '309', 'Percentage of women 21-64 years of age, who received one or more Pap tests to screen for cervical cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS124', 4, 'Cervical Cancer Screening', '0032', '309', 'Percentage of women 21-64 years of age, who received one or more Pap tests to screen for cervical cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS124', 5, 'Cervical Cancer Screening', '0032', '309', 'Percentage of women 21-64 years of age, who received one or more Pap tests to screen for cervical cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS153', 1, 'Chlamydia Screening for Women', '0033', '310', 'Percentage of women 16- 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period.', 'Population/Public Health.', 1, -1, false),
('CMS153', 2, 'Chlamydia Screening for Women', '0033', '310', 'Percentage of women 16- 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period.', 'Population/Public Health.', 1, -1, false),
('CMS153', 3, 'Chlamydia Screening for Women', '0033', '310', 'Percentage of women 16- 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period.', 'Population/Public Health.', 1, -1, false),
('CMS153', 4, 'Chlamydia Screening for Women', '0033', '310', 'Percentage of women 16- 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period.', 'Population/Public Health.', 1, -1, false),
('CMS153', 5, 'Chlamydia Screening for Women', '0033', '310', 'Percentage of women 16- 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period.', 'Population/Public Health.', 1, -1, false),
('CMS130', 1, 'Colorectal Cancer Screening', '0034', '113 GPRO PREV-6', 'Percentage of adults 50- 75 years of age who had appropriate screening for colorectal cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS130', 2, 'Colorectal Cancer Screening', '0034', '113 GPRO PREV-6', 'Percentage of adults 50- 75 years of age who had appropriate screening for colorectal cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS130', 3, 'Colorectal Cancer Screening', '0034', '113 GPRO PREV-6', 'Percentage of adults 50- 75 years of age who had appropriate screening for colorectal cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS130', 4, 'Colorectal Cancer Screening', '0034', '113 GPRO PREV-6', 'Percentage of adults 50- 75 years of age who had appropriate screening for colorectal cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS130', 5, 'Colorectal Cancer Screening', '0034', '113 GPRO PREV-6', 'Percentage of adults 50- 75 years of age who had appropriate screening for colorectal cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS126', 1, 'Use of Appropriate Medications for Asthma', '0036', '311', 'Percentage of patients 5- 64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS126', 2, 'Use of Appropriate Medications for Asthma', '0036', '311', 'Percentage of patients 5- 64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS126', 3, 'Use of Appropriate Medications for Asthma', '0036', '311', 'Percentage of patients 5- 64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS126', 4, 'Use of Appropriate Medications for Asthma', '0036', '311', 'Percentage of patients 5- 64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS126', 5, 'Use of Appropriate Medications for Asthma', '0036', '311', 'Percentage of patients 5- 64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS117', 1, 'Childhood Immunization Status', '0038', '240', 'Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.', 'Population/Public Health.', 1, -1, false),
('CMS117', 2, 'Childhood Immunization Status', '0038', '240', 'Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.', 'Population/Public Health.', 1, -1, false),
('CMS117', 3, 'Childhood Immunization Status', '0038', '240', 'Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.', 'Population/Public Health.', 1, -1, false),
('CMS117', 4, 'Childhood Immunization Status', '0038', '240', 'Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.', 'Population/Public Health.', 1, -1, false),
('CMS117', 5, 'Childhood Immunization Status', '0038', '240', 'Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.', 'Population/Public Health.', 1, -1, false),
('CMS127', 1, 'Pneumonia Vaccination Status for Older Adults', '0043', '111 GPRO PREV-8', 'Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS127', 2, 'Pneumonia Vaccination Status for Older Adults', '0043', '111 GPRO PREV-8', 'Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS127', 3, 'Pneumonia Vaccination Status for Older Adults', '0043', '111 GPRO PREV-8', 'Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS127', 4, 'Pneumonia Vaccination Status for Older Adults', '0043', '111 GPRO PREV-8', 'Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS127', 5, 'Pneumonia Vaccination Status for Older Adults', '0043', '111 GPRO PREV-8', 'Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS131', 1, 'Diabetes: Eye Exam', '0055', '117 GPRO DM-7', 'Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior to the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS131', 2, 'Diabetes: Eye Exam', '0055', '117 GPRO DM-7', 'Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior to the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS131', 3, 'Diabetes: Eye Exam', '0055', '117 GPRO DM-7', 'Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior to the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS131', 4, 'Diabetes: Eye Exam', '0055', '117 GPRO DM-7', 'Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior to the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS131', 5, 'Diabetes: Eye Exam', '0055', '117 GPRO DM-7', 'Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior to the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS123', 1, 'Diabetes: Foot Exam', '0056', '163', 'Percentage of patients aged 18-75 years of age with diabetes who had a foot exam during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS123', 2, 'Diabetes: Foot Exam', '0056', '163', 'Percentage of patients aged 18-75 years of age with diabetes who had a foot exam during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS123', 3, 'Diabetes: Foot Exam', '0056', '163', 'Percentage of patients aged 18-75 years of age with diabetes who had a foot exam during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS123', 4, 'Diabetes: Foot Exam', '0056', '163', 'Percentage of patients aged 18-75 years of age with diabetes who had a foot exam during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS123', 5, 'Diabetes: Foot Exam', '0056', '163', 'Percentage of patients aged 18-75 years of age with diabetes who had a foot exam during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS122', 1, 'Diabetes: Hemoglobin A1c Poor Control', '0059', '001 GPRO DM-2', 'Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS122', 2, 'Diabetes: Hemoglobin A1c Poor Control', '0059', '001 GPRO DM-2', 'Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS122', 3, 'Diabetes: Hemoglobin A1c Poor Control', '0059', '001 GPRO DM-2', 'Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS122', 4, 'Diabetes: Hemoglobin A1c Poor Control', '0059', '001 GPRO DM-2', 'Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS122', 5, 'Diabetes: Hemoglobin A1c Poor Control', '0059', '001 GPRO DM-2', 'Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS148', 1, 'Hemoglobin A1c Test for Pediatric Patients', '0060', '365', 'Percentage of patients 5-17 years of age with diabetes with an HbA1c test during the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS148', 2, 'Hemoglobin A1c Test for Pediatric Patients', '0060', '365', 'Percentage of patients 5-17 years of age with diabetes with an HbA1c test during the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS148', 3, 'Hemoglobin A1c Test for Pediatric Patients', '0060', '365', 'Percentage of patients 5-17 years of age with diabetes with an HbA1c test during the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS148', 4, 'Hemoglobin A1c Test for Pediatric Patients', '0060', '365', 'Percentage of patients 5-17 years of age with diabetes with an HbA1c test during the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS148', 5, 'Hemoglobin A1c Test for Pediatric Patients', '0060', '365', 'Percentage of patients 5-17 years of age with diabetes with an HbA1c test during the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS134', 1, 'Diabetes: Urine Protein Screening', '0062', '119', 'The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS134', 2, 'Diabetes: Urine Protein Screening', '0062', '119', 'The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS134', 3, 'Diabetes: Urine Protein Screening', '0062', '119', 'The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS134', 4, 'Diabetes: Urine Protein Screening', '0062', '119', 'The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS134', 5, 'Diabetes: Urine Protein Screening', '0062', '119', 'The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS164', 1, 'Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic', '0068', '204 GPRO IVD-2', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antithrombotic during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS164', 2, 'Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic', '0068', '204 GPRO IVD-2', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antithrombotic during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS164', 3, 'Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic', '0068', '204 GPRO IVD-2', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antithrombotic during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS164', 4, 'Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic', '0068', '204 GPRO IVD-2', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antithrombotic during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS164', 5, 'Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic', '0068', '204 GPRO IVD-2', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antithrombotic during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS154', 1, 'Appropriate Treatment for Children with Upper Respiratory Infection (URI)', '0069', '065', 'Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS154', 2, 'Appropriate Treatment for Children with Upper Respiratory Infection (URI)', '0069', '065', 'Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS154', 3, 'Appropriate Treatment for Children with Upper Respiratory Infection (URI)', '0069', '065', 'Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS154', 4, 'Appropriate Treatment for Children with Upper Respiratory Infection (URI)', '0069', '065', 'Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS154', 5, 'Appropriate Treatment for Children with Upper Respiratory Infection (URI)', '0069', '065', 'Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS145', 1, 'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)', '0070', '007', 'Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS145', 2, 'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)', '0070', '007', 'Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS145', 3, 'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)', '0070', '007', 'Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS145', 4, 'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)', '0070', '007', 'Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS145', 5, 'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)', '0070', '007', 'Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS144', 1, 'Heart Failure (HF): BetaBlocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0083', '008 GPRO HF-6', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS144', 2, 'Heart Failure (HF): BetaBlocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0083', '008 GPRO HF-6', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS144', 3, 'Heart Failure (HF): BetaBlocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0083', '008 GPRO HF-6', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS144', 4, 'Heart Failure (HF): BetaBlocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0083', '008 GPRO HF-6', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS144', 5, 'Heart Failure (HF): BetaBlocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0083', '008 GPRO HF-6', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS143', 1, 'Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation', '0086', '012', 'Percentage of patients aged 18 years and older with a diagnosis of primary openangle glaucoma (POAG) who have an optic nerve head evaluation during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS143', 2, 'Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation', '0086', '012', 'Percentage of patients aged 18 years and older with a diagnosis of primary openangle glaucoma (POAG) who have an optic nerve head evaluation during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS143', 3, 'Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation', '0086', '012', 'Percentage of patients aged 18 years and older with a diagnosis of primary openangle glaucoma (POAG) who have an optic nerve head evaluation during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS143', 4, 'Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation', '0086', '012', 'Percentage of patients aged 18 years and older with a diagnosis of primary openangle glaucoma (POAG) who have an optic nerve head evaluation during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS143', 5, 'Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation', '0086', '012', 'Percentage of patients aged 18 years and older with a diagnosis of primary openangle glaucoma (POAG) who have an optic nerve head evaluation during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS167', 1, 'Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy', '0088', '018', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS167', 2, 'Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy', '0088', '018', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS167', 3, 'Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy', '0088', '018', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS167', 4, 'Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy', '0088', '018', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS167', 5, 'Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy', '0088', '018', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS142', 1, 'Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care', '0089', '019', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS142', 2, 'Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care', '0089', '019', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS142', 3, 'Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care', '0089', '019', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS142', 4, 'Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care', '0089', '019', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS142', 5, 'Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care', '0089', '019', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS139', 1, 'Falls: Screening for Future Fall Risk', '0101', '318 GPRO CARE-2', 'Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.', 'Patient Safety', 1, -1, false),
('CMS139', 2, 'Falls: Screening for Future Fall Risk', '0101', '318 GPRO CARE-2', 'Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.', 'Patient Safety', 1, -1, false),
('CMS139', 3, 'Falls: Screening for Future Fall Risk', '0101', '318 GPRO CARE-2', 'Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.', 'Patient Safety', 1, -1, false),
('CMS139', 4, 'Falls: Screening for Future Fall Risk', '0101', '318 GPRO CARE-2', 'Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.', 'Patient Safety', 1, -1, false),
('CMS139', 5, 'Falls: Screening for Future Fall Risk', '0101', '318 GPRO CARE-2', 'Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.', 'Patient Safety', 1, -1, false),
('CMS161', 1, 'Adult Major Depressive Disorder (MDD): Suicide Risk Assessment', '0104', '107', 'Percentage of patients aged 18 years and older with a diagnosis of major depressive disorder (MDD) with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS161', 2, 'Adult Major Depressive Disorder (MDD): Suicide Risk Assessment', '0104', '107', 'Percentage of patients aged 18 years and older with a diagnosis of major depressive disorder (MDD) with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS161', 3, 'Adult Major Depressive Disorder (MDD): Suicide Risk Assessment', '0104', '107', 'Percentage of patients aged 18 years and older with a diagnosis of major depressive disorder (MDD) with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS161', 4, 'Adult Major Depressive Disorder (MDD): Suicide Risk Assessment', '0104', '107', 'Percentage of patients aged 18 years and older with a diagnosis of major depressive disorder (MDD) with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS161', 5, 'Adult Major Depressive Disorder (MDD): Suicide Risk Assessment', '0104', '107', 'Percentage of patients aged 18 years and older with a diagnosis of major depressive disorder (MDD) with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS128', 1, 'Anti-depressant Medication Management', '0105', '009', 'Percentage of patients 18 years of age and older who were diagnosed with major depression and treated with antidepressant medication, and who remained on antidepressant medication treatment. Two rates are reported.  Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks).  Percentage of patients who remained on an antidepressant medication for at least 180 days (6 months).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS128', 2, 'Anti-depressant Medication Management', '0105', '009', 'Percentage of patients 18 years of age and older who were diagnosed with major depression and treated with antidepressant medication, and who remained on antidepressant medication treatment. Two rates are reported.  Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks).  Percentage of patients who remained on an antidepressant medication for at least 180 days (6 months).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS128', 3, 'Anti-depressant Medication Management', '0105', '009', 'Percentage of patients 18 years of age and older who were diagnosed with major depression and treated with antidepressant medication, and who remained on antidepressant medication treatment. Two rates are reported.  Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks).  Percentage of patients who remained on an antidepressant medication for at least 180 days (6 months).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS128', 4, 'Anti-depressant Medication Management', '0105', '009', 'Percentage of patients 18 years of age and older who were diagnosed with major depression and treated with antidepressant medication, and who remained on antidepressant medication treatment. Two rates are reported.  Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks).  Percentage of patients who remained on an antidepressant medication for at least 180 days (6 months).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS128', 5, 'Anti-depressant Medication Management', '0105', '009', 'Percentage of patients 18 years of age and older who were diagnosed with major depression and treated with antidepressant medication, and who remained on antidepressant medication treatment. Two rates are reported.  Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks).  Percentage of patients who remained on an antidepressant medication for at least 180 days (6 months).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS157', 1, 'Oncology: Medical and Radiation - Pain Intensity Quantified', '0384', '143', 'Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified', 'Patient and Family Engagement.', 1, -1, false),
('CMS157', 2, 'Oncology: Medical and Radiation - Pain Intensity Quantified', '0384', '143', 'Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified', 'Patient and Family Engagement.', 1, -1, false),
('CMS157', 3, 'Oncology: Medical and Radiation - Pain Intensity Quantified', '0384', '143', 'Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified', 'Patient and Family Engagement.', 1, -1, false),
('CMS157', 4, 'Oncology: Medical and Radiation - Pain Intensity Quantified', '0384', '143', 'Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified', 'Patient and Family Engagement.', 1, -1, false),
('CMS157', 5, 'Oncology: Medical and Radiation - Pain Intensity Quantified', '0384', '143', 'Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified', 'Patient and Family Engagement.', 1, -1, false),
('CMS140', 1, 'Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer', '0387', '071', 'Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS140', 2, 'Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer', '0387', '071', 'Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS140', 3, 'Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer', '0387', '071', 'Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS140', 4, 'Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer', '0387', '071', 'Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS140', 5, 'Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer', '0387', '071', 'Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS52', 1, 'HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis', '0405', '160', 'Percentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS52', 2, 'HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis', '0405', '160', 'Percentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS52', 3, 'HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis', '0405', '160', 'Percentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS52', 4, 'HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis', '0405', '160', 'Percentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS52', 5, 'HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis', '0405', '160', 'Percentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS68', 1, 'Documentation of Current Medications in the Medical Record', '0419', '130 GPRO CARE-3', 'Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-thecounters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND  must contain the medications'' name, dosage, frequency and route of administration.', 'Patient Safety', 1, -1, false),
('CMS68', 2, 'Documentation of Current Medications in the Medical Record', '0419', '130 GPRO CARE-3', 'Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-thecounters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND  must contain the medications'' name, dosage, frequency and route of administration.', 'Patient Safety', 1, -1, false),
('CMS68', 3, 'Documentation of Current Medications in the Medical Record', '0419', '130 GPRO CARE-3', 'Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-thecounters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND  must contain the medications'' name, dosage, frequency and route of administration.', 'Patient Safety', 1, -1, false),
('CMS68', 4, 'Documentation of Current Medications in the Medical Record', '0419', '130 GPRO CARE-3', 'Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-thecounters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND  must contain the medications'' name, dosage, frequency and route of administration.', 'Patient Safety', 1, -1, false),
('CMS68', 5, 'Documentation of Current Medications in the Medical Record', '0419', '130 GPRO CARE-3', 'Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-thecounters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND  must contain the medications'' name, dosage, frequency and route of administration.', 'Patient Safety', 1, -1, false),
('CMS69', 1, 'Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan', '0421', '128 GPRO PREV-9', 'Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter.   Normal Parameters:  Age 65 years and older BMI => 23 and < 30 kg/m2 Age 18 - 64 years BMI => 18.5 and < 25 kg/m2', 'Population/Public Health.', 1, -1, false),
('CMS69', 2, 'Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan', '0421', '128 GPRO PREV-9', 'Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter.   Normal Parameters:  Age 65 years and older BMI => 23 and < 30 kg/m2 Age 18 - 64 years BMI => 18.5 and < 25 kg/m2', 'Population/Public Health.', 1, -1, false),
('CMS69', 3, 'Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan', '0421', '128 GPRO PREV-9', 'Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter.   Normal Parameters:  Age 65 years and older BMI => 23 and < 30 kg/m2 Age 18 - 64 years BMI => 18.5 and < 25 kg/m2', 'Population/Public Health.', 1, -1, false),
('CMS69', 4, 'Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan', '0421', '128 GPRO PREV-9', 'Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter.   Normal Parameters:  Age 65 years and older BMI => 23 and < 30 kg/m2 Age 18 - 64 years BMI => 18.5 and < 25 kg/m2', 'Population/Public Health.', 1, -1, false),
('CMS69', 5, 'Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan', '0421', '128 GPRO PREV-9', 'Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter.   Normal Parameters:  Age 65 years and older BMI => 23 and < 30 kg/m2 Age 18 - 64 years BMI => 18.5 and < 25 kg/m2', 'Population/Public Health.', 1, -1, false),
('CMS132', 1, 'Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures', '0564', '192', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence', 'Patient Safety', 1, -1, false),
('CMS132', 2, 'Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures', '0564', '192', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence', 'Patient Safety', 1, -1, false),
('CMS132', 3, 'Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures', '0564', '192', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence', 'Patient Safety', 1, -1, false),
('CMS132', 4, 'Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures', '0564', '192', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence', 'Patient Safety', 1, -1, false),
('CMS132', 5, 'Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures', '0564', '192', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence', 'Patient Safety', 1, -1, false),
('CMS133', 1, 'Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery', '0565', '191', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had bestcorrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS133', 2, 'Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery', '0565', '191', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had bestcorrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS133', 3, 'Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery', '0565', '191', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had bestcorrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS133', 4, 'Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery', '0565', '191', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had bestcorrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS133', 5, 'Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery', '0565', '191', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had bestcorrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS159', 1, 'Depression Remission at Twelve Months', '0710', '370 GPRO MH-1', 'Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at twelve months defined as PHQ-9 score less than 5. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS159', 2, 'Depression Remission at Twelve Months', '0710', '370 GPRO MH-1', 'Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at twelve months defined as PHQ-9 score less than 5. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS159', 3, 'Depression Remission at Twelve Months', '0710', '370 GPRO MH-1', 'Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at twelve months defined as PHQ-9 score less than 5. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS159', 4, 'Depression Remission at Twelve Months', '0710', '370 GPRO MH-1', 'Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at twelve months defined as PHQ-9 score less than 5. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS159', 5, 'Depression Remission at Twelve Months', '0710', '370 GPRO MH-1', 'Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at twelve months defined as PHQ-9 score less than 5. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS160', 1, 'Depression Utilization of the PHQ-9 Tool', '0712', '371', 'Adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a PHQ- 9 tool administered at least once during a 4-month period in which there was a qualifying visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS160', 2, 'Depression Utilization of the PHQ-9 Tool', '0712', '371', 'Adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a PHQ- 9 tool administered at least once during a 4-month period in which there was a qualifying visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS160', 3, 'Depression Utilization of the PHQ-9 Tool', '0712', '371', 'Adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a PHQ- 9 tool administered at least once during a 4-month period in which there was a qualifying visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS160', 4, 'Depression Utilization of the PHQ-9 Tool', '0712', '371', 'Adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a PHQ- 9 tool administered at least once during a 4-month period in which there was a qualifying visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS160', 5, 'Depression Utilization of the PHQ-9 Tool', '0712', '371', 'Adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a PHQ- 9 tool administered at least once during a 4-month period in which there was a qualifying visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS177', 1, 'Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment', '1365', '382', 'Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk', 'Patient Safety', 1, -1, false),
('CMS177', 2, 'Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment', '1365', '382', 'Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk', 'Patient Safety', 1, -1, false),
('CMS177', 3, 'Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment', '1365', '382', 'Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk', 'Patient Safety', 1, -1, false),
('CMS177', 4, 'Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment', '1365', '382', 'Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk', 'Patient Safety', 1, -1, false),
('CMS177', 5, 'Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment', '1365', '382', 'Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk', 'Patient Safety', 1, -1, false),
('CMS125', 1, 'Breast Cancer Screening', 'N/A', '112 GPRO PREV-5', 'Percentage of women 40-69 years of age who had a mammogram to screen for breast cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS125', 2, 'Breast Cancer Screening', 'N/A', '112 GPRO PREV-5', 'Percentage of women 40-69 years of age who had a mammogram to screen for breast cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS125', 3, 'Breast Cancer Screening', 'N/A', '112 GPRO PREV-5', 'Percentage of women 40-69 years of age who had a mammogram to screen for breast cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS125', 4, 'Breast Cancer Screening', 'N/A', '112 GPRO PREV-5', 'Percentage of women 40-69 years of age who had a mammogram to screen for breast cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS125', 5, 'Breast Cancer Screening', 'N/A', '112 GPRO PREV-5', 'Percentage of women 40-69 years of age who had a mammogram to screen for breast cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS163', 1, 'Diabetes: Low Density Lipoprotein (LDL) Management', 'N/A', '002', 'Percentage of patients 18-75 years of age with diabetes whose LDL-C was adequately controlled (<100 mg/dL) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS163', 2, 'Diabetes: Low Density Lipoprotein (LDL) Management', 'N/A', '002', 'Percentage of patients 18-75 years of age with diabetes whose LDL-C was adequately controlled (<100 mg/dL) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS163', 3, 'Diabetes: Low Density Lipoprotein (LDL) Management', 'N/A', '002', 'Percentage of patients 18-75 years of age with diabetes whose LDL-C was adequately controlled (<100 mg/dL) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS163', 4, 'Diabetes: Low Density Lipoprotein (LDL) Management', 'N/A', '002', 'Percentage of patients 18-75 years of age with diabetes whose LDL-C was adequately controlled (<100 mg/dL) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS163', 5, 'Diabetes: Low Density Lipoprotein (LDL) Management', 'N/A', '002', 'Percentage of patients 18-75 years of age with diabetes whose LDL-C was adequately controlled (<100 mg/dL) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS169', 1, 'Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use', 'N/A', '367', 'Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS169', 2, 'Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use', 'N/A', '367', 'Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS169', 3, 'Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use', 'N/A', '367', 'Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS169', 4, 'Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use', 'N/A', '367', 'Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS169', 5, 'Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use', 'N/A', '367', 'Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS62', 1, 'HIV/AIDS: Medical Visit', 'N/A', '368', 'Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year with a minimum of 90 days between each visit', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS62', 2, 'HIV/AIDS: Medical Visit', 'N/A', '368', 'Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year with a minimum of 90 days between each visit', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS62', 3, 'HIV/AIDS: Medical Visit', 'N/A', '368', 'Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year with a minimum of 90 days between each visit', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS62', 4, 'HIV/AIDS: Medical Visit', 'N/A', '368', 'Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year with a minimum of 90 days between each visit', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS62', 5, 'HIV/AIDS: Medical Visit', 'N/A', '368', 'Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year with a minimum of 90 days between each visit', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS75', 1, 'Children Who Have Dental Decay or Cavities', 'N/A', '378', 'Percentage of children, age 0-20 years, who have had tooth decay or cavities during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS75', 2, 'Children Who Have Dental Decay or Cavities', 'N/A', '378', 'Percentage of children, age 0-20 years, who have had tooth decay or cavities during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS75', 3, 'Children Who Have Dental Decay or Cavities', 'N/A', '378', 'Percentage of children, age 0-20 years, who have had tooth decay or cavities during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS75', 4, 'Children Who Have Dental Decay or Cavities', 'N/A', '378', 'Percentage of children, age 0-20 years, who have had tooth decay or cavities during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS75', 5, 'Children Who Have Dental Decay or Cavities', 'N/A', '378', 'Percentage of children, age 0-20 years, who have had tooth decay or cavities during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS149', 1, 'Dementia: Cognitive Assessment', 'N/A', '281', 'Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12  month period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS149', 2, 'Dementia: Cognitive Assessment', 'N/A', '281', 'Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12  month period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS149', 3, 'Dementia: Cognitive Assessment', 'N/A', '281', 'Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12  month period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS149', 4, 'Dementia: Cognitive Assessment', 'N/A', '281', 'Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12  month period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS149', 5, 'Dementia: Cognitive Assessment', 'N/A', '281', 'Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12  month period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS50', 1, 'Closing the Referral Loop: Receipt of Specialist Report', 'N/A', '374', 'Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.', 'Care Coordination.', 1, -1, false),
('CMS50', 2, 'Closing the Referral Loop: Receipt of Specialist Report', 'N/A', '374', 'Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.', 'Care Coordination.', 1, -1, false),
('CMS50', 3, 'Closing the Referral Loop: Receipt of Specialist Report', 'N/A', '374', 'Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.', 'Care Coordination.', 1, -1, false),
('CMS50', 4, 'Closing the Referral Loop: Receipt of Specialist Report', 'N/A', '374', 'Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.', 'Care Coordination.', 1, -1, false),
('CMS50', 5, 'Closing the Referral Loop: Receipt of Specialist Report', 'N/A', '374', 'Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.', 'Care Coordination.', 1, -1, false),
('CMS66', 1, 'Functional Status Assessment for Knee Replacement', 'N/A', '375', 'Percentage of patients aged 18 years and older with primary total knee arthroplasty (TKA) who completed baseline and follow-up (patient-reported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS66', 2, 'Functional Status Assessment for Knee Replacement', 'N/A', '375', 'Percentage of patients aged 18 years and older with primary total knee arthroplasty (TKA) who completed baseline and follow-up (patient-reported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS66', 3, 'Functional Status Assessment for Knee Replacement', 'N/A', '375', 'Percentage of patients aged 18 years and older with primary total knee arthroplasty (TKA) who completed baseline and follow-up (patient-reported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS66', 4, 'Functional Status Assessment for Knee Replacement', 'N/A', '375', 'Percentage of patients aged 18 years and older with primary total knee arthroplasty (TKA) who completed baseline and follow-up (patient-reported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS66', 5, 'Functional Status Assessment for Knee Replacement', 'N/A', '375', 'Percentage of patients aged 18 years and older with primary total knee arthroplasty (TKA) who completed baseline and follow-up (patient-reported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS56', 1, 'Functional Status Assessment for Hip Replacemen', 'N/A', '376', 'Percentage of patients aged 18 years and older with primary total hip arthroplasty (THA) who completed baseline and follow-up (patientreported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS56', 2, 'Functional Status Assessment for Hip Replacemen', 'N/A', '376', 'Percentage of patients aged 18 years and older with primary total hip arthroplasty (THA) who completed baseline and follow-up (patientreported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS56', 3, 'Functional Status Assessment for Hip Replacemen', 'N/A', '376', 'Percentage of patients aged 18 years and older with primary total hip arthroplasty (THA) who completed baseline and follow-up (patientreported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS56', 4, 'Functional Status Assessment for Hip Replacemen', 'N/A', '376', 'Percentage of patients aged 18 years and older with primary total hip arthroplasty (THA) who completed baseline and follow-up (patientreported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS56', 5, 'Functional Status Assessment for Hip Replacemen', 'N/A', '376', 'Percentage of patients aged 18 years and older with primary total hip arthroplasty (THA) who completed baseline and follow-up (patientreported) functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS179', 1, 'ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range', 'N/A', '380', 'Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the measurement period.', 'Patient Safety.', 1, -1, false),
('CMS179', 2, 'ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range', 'N/A', '380', 'Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the measurement period.', 'Patient Safety.', 1, -1, false),
('CMS179', 3, 'ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range', 'N/A', '380', 'Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the measurement period.', 'Patient Safety.', 1, -1, false),
('CMS179', 4, 'ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range', 'N/A', '380', 'Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the measurement period.', 'Patient Safety.', 1, -1, false),
('CMS179', 5, 'ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range', 'N/A', '380', 'Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the measurement period.', 'Patient Safety.', 1, -1, false),
('CMS22', 1, 'Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented', 'N/A', '317 GPRO PREV-11', 'Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated', 'Population/Public Health.', 1, -1, false),
('CMS22', 2, 'Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented', 'N/A', '317 GPRO PREV-11', 'Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated', 'Population/Public Health.', 1, -1, false),
('CMS22', 3, 'Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented', 'N/A', '317 GPRO PREV-11', 'Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated', 'Population/Public Health.', 1, -1, false),
('CMS22', 4, 'Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented', 'N/A', '317 GPRO PREV-11', 'Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated', 'Population/Public Health.', 1, -1, false),
('CMS22', 5, 'Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented', 'N/A', '317 GPRO PREV-11', 'Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated', 'Population/Public Health.', 1, -1, false),
('CMS77', 1, 'HIV/AIDS: RNA control for Patients with HIV', 'N/A', '381', 'Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit, whose most recent HIV RNA level is <200 copies/mL.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS77', 2, 'HIV/AIDS: RNA control for Patients with HIV', 'N/A', '381', 'Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit, whose most recent HIV RNA level is <200 copies/mL.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS77', 3, 'HIV/AIDS: RNA control for Patients with HIV', 'N/A', '381', 'Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit, whose most recent HIV RNA level is <200 copies/mL.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS77', 4, 'HIV/AIDS: RNA control for Patients with HIV', 'N/A', '381', 'Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit, whose most recent HIV RNA level is <200 copies/mL.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS77', 5, 'HIV/AIDS: RNA control for Patients with HIV', 'N/A', '381', 'Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit, whose most recent HIV RNA level is <200 copies/mL.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS158', 1, 'Pregnant women that had HBsAg testing', 'N/A', '369', 'This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS158', 2, 'Pregnant women that had HBsAg testing', 'N/A', '369', 'This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS158', 3, 'Pregnant women that had HBsAg testing', 'N/A', '369', 'This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS158', 4, 'Pregnant women that had HBsAg testing', 'N/A', '369', 'This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS158', 5, 'Pregnant women that had HBsAg testing', 'N/A', '369', 'This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS166', 1, 'Use of Imaging Studies for Low Back Pain', '0052', '312', 'Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS166', 2, 'Use of Imaging Studies for Low Back Pain', '0052', '312', 'Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS166', 3, 'Use of Imaging Studies for Low Back Pain', '0052', '312', 'Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS166', 4, 'Use of Imaging Studies for Low Back Pain', '0052', '312', 'Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS166', 5, 'Use of Imaging Studies for Low Back Pain', '0052', '312', 'Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS166', 6, 'Use of Imaging Studies for Low Back Pain', '0052', '312', 'Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS136', 1, 'ADHD: Follow-Up Care for Children Prescribed AttentionDeficit/Hyperactivi ty Disorder (ADHD) Medication', '0108', '366', 'Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.  Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.  Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS136', 2, 'ADHD: Follow-Up Care for Children Prescribed AttentionDeficit/Hyperactivi ty Disorder (ADHD) Medication', '0108', '366', 'Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.  Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.  Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS136', 3, 'ADHD: Follow-Up Care for Children Prescribed AttentionDeficit/Hyperactivi ty Disorder (ADHD) Medication', '0108', '366', 'Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.  Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.  Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS136', 4, 'ADHD: Follow-Up Care for Children Prescribed AttentionDeficit/Hyperactivi ty Disorder (ADHD) Medication', '0108', '366', 'Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.  Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.  Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS136', 5, 'ADHD: Follow-Up Care for Children Prescribed AttentionDeficit/Hyperactivi ty Disorder (ADHD) Medication', '0108', '366', 'Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.  Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.  Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS136', 6, 'ADHD: Follow-Up Care for Children Prescribed AttentionDeficit/Hyperactivi ty Disorder (ADHD) Medication', '0108', '366', 'Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.  Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.  Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS2', 1, 'Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan', '0418', '134 GPRO PREV-12', 'Percentage of patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen.', 'Population/Public Health.', 1, -1, false),
('CMS2', 2, 'Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan', '0418', '134 GPRO PREV-12', 'Percentage of patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen.', 'Population/Public Health.', 1, -1, false),
('CMS2', 3, 'Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan', '0418', '134 GPRO PREV-12', 'Percentage of patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen.', 'Population/Public Health.', 1, -1, false),
('CMS2', 4, 'Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan', '0418', '134 GPRO PREV-12', 'Percentage of patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen.', 'Population/Public Health.', 1, -1, false),
('CMS2', 5, 'Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan', '0418', '134 GPRO PREV-12', 'Percentage of patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen.', 'Population/Public Health.', 1, -1, false),
('CMS2', 6, 'Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan', '0418', '134 GPRO PREV-12', 'Percentage of patients aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen.', 'Population/Public Health.', 1, -1, false),
('CMS90', 1, 'Functional Status Assessment for Complex Chronic Conditions', 'N/A', '377', 'Percentage of patients aged 65 years and older with heart failure who completed initial and follow-up patient reported functional status assessments', 'Patient and Family Engagement.', 1, -1, false),
('CMS90', 2, 'Functional Status Assessment for Complex Chronic Conditions', 'N/A', '377', 'Percentage of patients aged 65 years and older with heart failure who completed initial and follow-up patient reported functional status assessments', 'Patient and Family Engagement.', 1, -1, false),
('CMS90', 3, 'Functional Status Assessment for Complex Chronic Conditions', 'N/A', '377', 'Percentage of patients aged 65 years and older with heart failure who completed initial and follow-up patient reported functional status assessments', 'Patient and Family Engagement.', 1, -1, false),
('CMS90', 4, 'Functional Status Assessment for Complex Chronic Conditions', 'N/A', '377', 'Percentage of patients aged 65 years and older with heart failure who completed initial and follow-up patient reported functional status assessments', 'Patient and Family Engagement.', 1, -1, false),
('CMS90', 5, 'Functional Status Assessment for Complex Chronic Conditions', 'N/A', '377', 'Percentage of patients aged 65 years and older with heart failure who completed initial and follow-up patient reported functional status assessments', 'Patient and Family Engagement.', 1, -1, false),
('CMS90', 6, 'Functional Status Assessment for Complex Chronic Conditions', 'N/A', '377', 'Percentage of patients aged 65 years and older with heart failure who completed initial and follow-up patient reported functional status assessments', 'Patient and Family Engagement.', 1, -1, false),
('CMS147', 1, 'Preventive Care and Screening: Influenza Immunization', '0041', '110 GPRO PREV-7', 'Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization', 'Population/Public Health.', 1, -1, false),
('CMS147', 2, 'Preventive Care and Screening: Influenza Immunization', '0041', '110 GPRO PREV-7', 'Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization', 'Population/Public Health.', 1, -1, false),
('CMS147', 3, 'Preventive Care and Screening: Influenza Immunization', '0041', '110 GPRO PREV-7', 'Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization', 'Population/Public Health.', 1, -1, false),
('CMS147', 4, 'Preventive Care and Screening: Influenza Immunization', '0041', '110 GPRO PREV-7', 'Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization', 'Population/Public Health.', 1, -1, false),
('CMS147', 5, 'Preventive Care and Screening: Influenza Immunization', '0041', '110 GPRO PREV-7', 'Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization', 'Population/Public Health.', 1, -1, false),
('CMS147', 6, 'Preventive Care and Screening: Influenza Immunization', '0041', '110 GPRO PREV-7', 'Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization', 'Population/Public Health.', 1, -1, false),
('CMS135', 1, 'Heart Failure (HF): AngiotensinConverting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0081', '005', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS135', 2, 'Heart Failure (HF): AngiotensinConverting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0081', '005', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS135', 3, 'Heart Failure (HF): AngiotensinConverting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0081', '005', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS135', 4, 'Heart Failure (HF): AngiotensinConverting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0081', '005', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS135', 5, 'Heart Failure (HF): AngiotensinConverting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '0081', '005', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS182', 1, 'Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control', 'N/A', '241', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose LDL-C was adequately controlled (< 100 mg/dL).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS182', 2, 'Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control', 'N/A', '241', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose LDL-C was adequately controlled (< 100 mg/dL).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS182', 3, 'Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control', 'N/A', '241', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose LDL-C was adequately controlled (< 100 mg/dL).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS182', 4, 'Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control', 'N/A', '241', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose LDL-C was adequately controlled (< 100 mg/dL).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS182', 5, 'Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control', 'N/A', '241', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose LDL-C was adequately controlled (< 100 mg/dL).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS182', 6, 'Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control', 'N/A', '241', 'Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose LDL-C was adequately controlled (< 100 mg/dL).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS31', 1, 'Hearing Screening Prior To Hospital Discharge', '1354', null, 'This measure assesses the proportion of births that have been screened for hearing loss before hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS31', 2, 'Hearing Screening Prior To Hospital Discharge', '1354', null, 'This measure assesses the proportion of births that have been screened for hearing loss before hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS31', 3, 'Hearing Screening Prior To Hospital Discharge', '1354', null, 'This measure assesses the proportion of births that have been screened for hearing loss before hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS31', 4, 'Hearing Screening Prior To Hospital Discharge', '1354', null, 'This measure assesses the proportion of births that have been screened for hearing loss before hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS31', 5, 'Hearing Screening Prior To Hospital Discharge', '1354', null, 'This measure assesses the proportion of births that have been screened for hearing loss before hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS100', 1, 'Aspirin Prescribed at Discharge', '0142', null, 'Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS100', 2, 'Aspirin Prescribed at Discharge', '0142', null, 'Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS100', 3, 'Aspirin Prescribed at Discharge', '0142', null, 'Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS100', 4, 'Aspirin Prescribed at Discharge', '0142', null, 'Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS100', 5, 'Aspirin Prescribed at Discharge', '0142', null, 'Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS53', 1, 'Primary PCI Received Within 90 Minutes of Hospital Arrival', '0163', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS53', 2, 'Primary PCI Received Within 90 Minutes of Hospital Arrival', '0163', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS53', 3, 'Primary PCI Received Within 90 Minutes of Hospital Arrival', '0163', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS53', 4, 'Primary PCI Received Within 90 Minutes of Hospital Arrival', '0163', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS53', 5, 'Primary PCI Received Within 90 Minutes of Hospital Arrival', '0163', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS60', 1, 'Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival', '0164', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS60', 2, 'Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival', '0164', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS60', 3, 'Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival', '0164', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS60', 4, 'Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival', '0164', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS60', 5, 'Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival', '0164', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS108', 1, 'Venous Thromboembolism Prophylaxis', '0371', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.', 'Patient Safety', 2, -1, false),
('CMS108', 2, 'Venous Thromboembolism Prophylaxis', '0371', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.', 'Patient Safety', 2, -1, false),
('CMS108', 3, 'Venous Thromboembolism Prophylaxis', '0371', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.', 'Patient Safety', 2, -1, false),
('CMS108', 4, 'Venous Thromboembolism Prophylaxis', '0371', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.', 'Patient Safety', 2, -1, false),
('CMS108', 5, 'Venous Thromboembolism Prophylaxis', '0371', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.', 'Patient Safety', 2, -1, false),
('CMS190', 1, 'Intensive Care Unit Venous Thromboembolism Prophylaxis', '0372', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).', 'Patient Safety', 2, -1, false),
('CMS190', 2, 'Intensive Care Unit Venous Thromboembolism Prophylaxis', '0372', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).', 'Patient Safety', 2, -1, false),
('CMS190', 3, 'Intensive Care Unit Venous Thromboembolism Prophylaxis', '0372', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).', 'Patient Safety', 2, -1, false),
('CMS190', 4, 'Intensive Care Unit Venous Thromboembolism Prophylaxis', '0372', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).', 'Patient Safety', 2, -1, false),
('CMS190', 5, 'Intensive Care Unit Venous Thromboembolism Prophylaxis', '0372', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).', 'Patient Safety', 2, -1, false),
('CMS73', 1, 'Venous Thromboembolism Patients with Anticoagulation Overlap Therapy', '0373', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they should be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications or have a reason for discontinuation of overlap therapy', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS73', 2, 'Venous Thromboembolism Patients with Anticoagulation Overlap Therapy', '0373', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they should be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications or have a reason for discontinuation of overlap therapy', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS73', 3, 'Venous Thromboembolism Patients with Anticoagulation Overlap Therapy', '0373', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they should be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications or have a reason for discontinuation of overlap therapy', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS73', 4, 'Venous Thromboembolism Patients with Anticoagulation Overlap Therapy', '0373', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they should be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications or have a reason for discontinuation of overlap therapy', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS73', 5, 'Venous Thromboembolism Patients with Anticoagulation Overlap Therapy', '0373', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they should be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications or have a reason for discontinuation of overlap therapy', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS104', 1, 'Discharged on Antithrombotic Therapy', '0435', null, 'Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS104', 2, 'Discharged on Antithrombotic Therapy', '0435', null, 'Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS104', 3, 'Discharged on Antithrombotic Therapy', '0435', null, 'Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS104', 4, 'Discharged on Antithrombotic Therapy', '0435', null, 'Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS104', 5, 'Discharged on Antithrombotic Therapy', '0435', null, 'Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS72', 1, 'Antithrombotic Therapy By End of Hospital Day 2', '0438', null, 'Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS72', 2, 'Antithrombotic Therapy By End of Hospital Day 2', '0438', null, 'Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS72', 3, 'Antithrombotic Therapy By End of Hospital Day 2', '0438', null, 'Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS72', 4, 'Antithrombotic Therapy By End of Hospital Day 2', '0438', null, 'Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS72', 5, 'Antithrombotic Therapy By End of Hospital Day 2', '0438', null, 'Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS105', 1, 'Discharged on Statin Medication', '0439', null, 'Ischemic stroke patients who are prescribed statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS105', 2, 'Discharged on Statin Medication', '0439', null, 'Ischemic stroke patients who are prescribed statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS105', 3, 'Discharged on Statin Medication', '0439', null, 'Ischemic stroke patients who are prescribed statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS105', 4, 'Discharged on Statin Medication', '0439', null, 'Ischemic stroke patients who are prescribed statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS105', 5, 'Discharged on Statin Medication', '0439', null, 'Ischemic stroke patients who are prescribed statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS102', 1, 'Assessed for Rehabilitation', '0441', null, 'Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.', 'Care Coordination', 2, -1, false),
('CMS102', 2, 'Assessed for Rehabilitation', '0441', null, 'Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.', 'Care Coordination', 2, -1, false),
('CMS102', 3, 'Assessed for Rehabilitation', '0441', null, 'Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.', 'Care Coordination', 2, -1, false),
('CMS102', 4, 'Assessed for Rehabilitation', '0441', null, 'Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.', 'Care Coordination', 2, -1, false),
('CMS102', 5, 'Assessed for Rehabilitation', '0441', null, 'Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.', 'Care Coordination', 2, -1, false),
('CMS113', 1, 'Elective Delivery', '0469', null, 'Patients with elective vaginal deliveries or elective cesarean births at >= 37 and < 39 weeks of gestation completed', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS113', 2, 'Elective Delivery', '0469', null, 'Patients with elective vaginal deliveries or elective cesarean births at >= 37 and < 39 weeks of gestation completed', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS113', 3, 'Elective Delivery', '0469', null, 'Patients with elective vaginal deliveries or elective cesarean births at >= 37 and < 39 weeks of gestation completed', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS113', 4, 'Elective Delivery', '0469', null, 'Patients with elective vaginal deliveries or elective cesarean births at >= 37 and < 39 weeks of gestation completed', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS113', 5, 'Elective Delivery', '0469', null, 'Patients with elective vaginal deliveries or elective cesarean births at >= 37 and < 39 weeks of gestation completed', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS9', 1, 'Exclusive Breast Milk Feeding', '0480', null, 'Exclusive breast milk feeding during the newborn''s entire hospitalization.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS9', 2, 'Exclusive Breast Milk Feeding', '0480', null, 'Exclusive breast milk feeding during the newborn''s entire hospitalization.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS9', 3, 'Exclusive Breast Milk Feeding', '0480', null, 'Exclusive breast milk feeding during the newborn''s entire hospitalization.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS9', 4, 'Exclusive Breast Milk Feeding', '0480', null, 'Exclusive breast milk feeding during the newborn''s entire hospitalization.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS9', 5, 'Exclusive Breast Milk Feeding', '0480', null, 'Exclusive breast milk feeding during the newborn''s entire hospitalization.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS55', 1, 'Median Time from ED Arrival to ED Departure for Admitted ED Patients', '0495', null, 'Median time from emergency department admission to time of discharge from the emergency room for patients admitted to the facility from the emergency department.', 'Patient and Family Engagement', 2, -1, false),
('CMS55', 2, 'Median Time from ED Arrival to ED Departure for Admitted ED Patients', '0495', null, 'Median time from emergency department admission to time of discharge from the emergency room for patients admitted to the facility from the emergency department.', 'Patient and Family Engagement', 2, -1, false),
('CMS55', 3, 'Median Time from ED Arrival to ED Departure for Admitted ED Patients', '0495', null, 'Median time from emergency department admission to time of discharge from the emergency room for patients admitted to the facility from the emergency department.', 'Patient and Family Engagement', 2, -1, false),
('CMS55', 4, 'Median Time from ED Arrival to ED Departure for Admitted ED Patients', '0495', null, 'Median time from emergency department admission to time of discharge from the emergency room for patients admitted to the facility from the emergency department.', 'Patient and Family Engagement', 2, -1, false),
('CMS55', 5, 'Median Time from ED Arrival to ED Departure for Admitted ED Patients', '0495', null, 'Median time from emergency department admission to time of discharge from the emergency room for patients admitted to the facility from the emergency department.', 'Patient and Family Engagement', 2, -1, false),
('CMS111', 1, 'Median Admit Decision Time to ED Departure Time for Admitted Patients', '0497', null, 'Median time (in minutes) from admit decision time to time of discharge from the emergency department for emergency department patients admitted to inpatient status.', 'Patient and Family Engagement', 2, -1, false),
('CMS111', 2, 'Median Admit Decision Time to ED Departure Time for Admitted Patients', '0497', null, 'Median time (in minutes) from admit decision time to time of discharge from the emergency department for emergency department patients admitted to inpatient status.', 'Patient and Family Engagement', 2, -1, false),
('CMS111', 3, 'Median Admit Decision Time to ED Departure Time for Admitted Patients', '0497', null, 'Median time (in minutes) from admit decision time to time of discharge from the emergency department for emergency department patients admitted to inpatient status.', 'Patient and Family Engagement', 2, -1, false),
('CMS111', 4, 'Median Admit Decision Time to ED Departure Time for Admitted Patients', '0497', null, 'Median time (in minutes) from admit decision time to time of discharge from the emergency department for emergency department patients admitted to inpatient status.', 'Patient and Family Engagement', 2, -1, false),
('CMS111', 5, 'Median Admit Decision Time to ED Departure Time for Admitted Patients', '0497', null, 'Median time (in minutes) from admit decision time to time of discharge from the emergency department for emergency department patients admitted to inpatient status.', 'Patient and Family Engagement', 2, -1, false),
('CMS185', 1, 'Healthy Term Newborn', '0716', null, 'Percent of term singleton live births (excluding those with diagnoses originating in the fetal period) who DO NOT have significant complications during b', 'Patient Safety', 2, -1, false),
('CMS185', 2, 'Healthy Term Newborn', '0716', null, 'Percent of term singleton live births (excluding those with diagnoses originating in the fetal period) who DO NOT have significant complications during b', 'Patient Safety', 2, -1, false),
('CMS185', 3, 'Healthy Term Newborn', '0716', null, 'Percent of term singleton live births (excluding those with diagnoses originating in the fetal period) who DO NOT have significant complications during b', 'Patient Safety', 2, -1, false),
('CMS185', 4, 'Healthy Term Newborn', '0716', null, 'Percent of term singleton live births (excluding those with diagnoses originating in the fetal period) who DO NOT have significant complications during b', 'Patient Safety', 2, -1, false),
('CMS185', 5, 'Healthy Term Newborn', '0716', null, 'Percent of term singleton live births (excluding those with diagnoses originating in the fetal period) who DO NOT have significant complications during b', 'Patient Safety', 2, -1, false),
('CMS107', 1, 'Stroke Education', 'N/A', null, 'Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.', 'Patient and Family Engagement', 2, -1, false),
('CMS107', 2, 'Stroke Education', 'N/A', null, 'Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.', 'Patient and Family Engagement', 2, -1, false),
('CMS107', 3, 'Stroke Education', 'N/A', null, 'Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.', 'Patient and Family Engagement', 2, -1, false),
('CMS107', 4, 'Stroke Education', 'N/A', null, 'Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.', 'Patient and Family Engagement', 2, -1, false),
('CMS107', 5, 'Stroke Education', 'N/A', null, 'Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.', 'Patient and Family Engagement', 2, -1, false),
('CMS109', 1, 'Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS109', 2, 'Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS109', 3, 'Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS109', 4, 'Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS109', 5, 'Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS110', 1, 'Venous Thromboembolism Discharge Instructions', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, home care, court/law enforcement or home on hospice care on warfarin with written discharge instructions that address all four criteria: compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/ interactions.', 'Patient and Family Engagement', 2, -1, false),
('CMS110', 2, 'Venous Thromboembolism Discharge Instructions', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, home care, court/law enforcement or home on hospice care on warfarin with written discharge instructions that address all four criteria: compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/ interactions.', 'Patient and Family Engagement', 2, -1, false),
('CMS110', 3, 'Venous Thromboembolism Discharge Instructions', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, home care, court/law enforcement or home on hospice care on warfarin with written discharge instructions that address all four criteria: compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/ interactions.', 'Patient and Family Engagement', 2, -1, false),
('CMS110', 4, 'Venous Thromboembolism Discharge Instructions', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, home care, court/law enforcement or home on hospice care on warfarin with written discharge instructions that address all four criteria: compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/ interactions.', 'Patient and Family Engagement', 2, -1, false),
('CMS110', 5, 'Venous Thromboembolism Discharge Instructions', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, home care, court/law enforcement or home on hospice care on warfarin with written discharge instructions that address all four criteria: compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/ interactions.', 'Patient and Family Engagement', 2, -1, false),
('CMS114', 1, 'Incidence of PotentiallyPreventable Venous Thromboembolism', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present at admission) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date.', 'Patient Safety', 2, -1, false),
('CMS114', 2, 'Incidence of PotentiallyPreventable Venous Thromboembolism', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present at admission) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date.', 'Patient Safety', 2, -1, false),
('CMS114', 3, 'Incidence of PotentiallyPreventable Venous Thromboembolism', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present at admission) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date.', 'Patient Safety', 2, -1, false),
('CMS114', 4, 'Incidence of PotentiallyPreventable Venous Thromboembolism', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present at admission) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date.', 'Patient Safety', 2, -1, false),
('CMS114', 5, 'Incidence of PotentiallyPreventable Venous Thromboembolism', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present at admission) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date.', 'Patient Safety', 2, -1, false),
('CMS141', 1, 'Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients', '0385', '072', 'Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS141', 2, 'Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients', '0385', '072', 'Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS141', 3, 'Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients', '0385', '072', 'Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS141', 4, 'Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients', '0385', '072', 'Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS141', 5, 'Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients', '0385', '072', 'Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS141', 6, 'Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients', '0385', '072', 'Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS129', 1, 'Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients', '0389', '102', 'Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam  adiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS129', 2, 'Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients', '0389', '102', 'Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam  adiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS129', 3, 'Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients', '0389', '102', 'Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam  adiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS129', 4, 'Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients', '0389', '102', 'Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam  adiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS129', 5, 'Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients', '0389', '102', 'Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam  adiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS129', 6, 'Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients', '0389', '102', 'Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam  adiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS74', 1, 'Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists', 'N/A', '379', 'Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS74', 2, 'Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists', 'N/A', '379', 'Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS74', 3, 'Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists', 'N/A', '379', 'Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS74', 4, 'Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists', 'N/A', '379', 'Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS74', 5, 'Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists', 'N/A', '379', 'Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS74', 6, 'Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists', 'N/A', '379', 'Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS61', 1, 'Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed', 'N/A', '316', 'Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDLC test has been performed.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS61', 2, 'Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed', 'N/A', '316', 'Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDLC test has been performed.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS61', 3, 'Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed', 'N/A', '316', 'Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDLC test has been performed.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS61', 4, 'Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed', 'N/A', '316', 'Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDLC test has been performed.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS61', 5, 'Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed', 'N/A', '316', 'Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDLC test has been performed.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS61', 6, 'Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed', 'N/A', '316', 'Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDLC test has been performed.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS64', 1, 'Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDLC)', 'N/A', '316', 'Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose riskstratified fasting LDL-C is at or below the recommended LDL-C goal.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS64', 2, 'Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDLC)', 'N/A', '316', 'Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose riskstratified fasting LDL-C is at or below the recommended LDL-C goal.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS64', 3, 'Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDLC)', 'N/A', '316', 'Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose riskstratified fasting LDL-C is at or below the recommended LDL-C goal.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS64', 4, 'Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDLC)', 'N/A', '316', 'Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose riskstratified fasting LDL-C is at or below the recommended LDL-C goal.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS64', 5, 'Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDLC)', 'N/A', '316', 'Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose riskstratified fasting LDL-C is at or below the recommended LDL-C goal.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS64', 6, 'Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDLC)', 'N/A', '316', 'Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose riskstratified fasting LDL-C is at or below the recommended LDL-C goal.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS65', 1, 'Hypertension: Improvement in Blood Pressure', 'N/A', '373', 'Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS65', 2, 'Hypertension: Improvement in Blood Pressure', 'N/A', '373', 'Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS65', 3, 'Hypertension: Improvement in Blood Pressure', 'N/A', '373', 'Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS65', 4, 'Hypertension: Improvement in Blood Pressure', 'N/A', '373', 'Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS65', 5, 'Hypertension: Improvement in Blood Pressure', 'N/A', '373', 'Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS65', 6, 'Hypertension: Improvement in Blood Pressure', 'N/A', '373', 'Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS188', 1, 'Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients', '0147', null, '(PN-6) Immunocompetent patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 1) Immunocompetent ICU patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 2) Immunocompetent nonIntensive Care Unit (ICU) patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS188', 2, 'Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients', '0147', null, '(PN-6) Immunocompetent patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 1) Immunocompetent ICU patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 2) Immunocompetent nonIntensive Care Unit (ICU) patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS188', 3, 'Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients', '0147', null, '(PN-6) Immunocompetent patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 1) Immunocompetent ICU patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 2) Immunocompetent nonIntensive Care Unit (ICU) patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS188', 4, 'Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients', '0147', null, '(PN-6) Immunocompetent patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 1) Immunocompetent ICU patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 2) Immunocompetent nonIntensive Care Unit (ICU) patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS188', 5, 'Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients', '0147', null, '(PN-6) Immunocompetent patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 1) Immunocompetent ICU patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 2) Immunocompetent nonIntensive Care Unit (ICU) patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS188', 6, 'Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients', '0147', null, '(PN-6) Immunocompetent patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 1) Immunocompetent ICU patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines (Population 2) Immunocompetent nonIntensive Care Unit (ICU) patients with CommunityAcquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS71', 1, 'Anticoagulation Therapy for Atrial Fibrillation/Flutter', '0436', null, 'Ischemic stroke patients with atrial fibrillation/ flutter who are prescribed anticoagulation therapy at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS71', 2, 'Anticoagulation Therapy for Atrial Fibrillation/Flutter', '0436', null, 'Ischemic stroke patients with atrial fibrillation/ flutter who are prescribed anticoagulation therapy at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS71', 3, 'Anticoagulation Therapy for Atrial Fibrillation/Flutter', '0436', null, 'Ischemic stroke patients with atrial fibrillation/ flutter who are prescribed anticoagulation therapy at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS71', 4, 'Anticoagulation Therapy for Atrial Fibrillation/Flutter', '0436', null, 'Ischemic stroke patients with atrial fibrillation/ flutter who are prescribed anticoagulation therapy at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS71', 5, 'Anticoagulation Therapy for Atrial Fibrillation/Flutter', '0436', null, 'Ischemic stroke patients with atrial fibrillation/ flutter who are prescribed anticoagulation therapy at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS71', 6, 'Anticoagulation Therapy for Atrial Fibrillation/Flutter', '0436', null, 'Ischemic stroke patients with atrial fibrillation/ flutter who are prescribed anticoagulation therapy at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS91', 1, 'Thrombolytic Therapy', '0437', null, 'Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom t-PA was initiated at this hospital within 3 hours of time last known well.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS91', 2, 'Thrombolytic Therapy', '0437', null, 'Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom t-PA was initiated at this hospital within 3 hours of time last known well.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS91', 3, 'Thrombolytic Therapy', '0437', null, 'Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom t-PA was initiated at this hospital within 3 hours of time last known well.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS91', 4, 'Thrombolytic Therapy', '0437', null, 'Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom t-PA was initiated at this hospital within 3 hours of time last known well.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS91', 5, 'Thrombolytic Therapy', '0437', null, 'Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom t-PA was initiated at this hospital within 3 hours of time last known well.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS91', 6, 'Thrombolytic Therapy', '0437', null, 'Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom t-PA was initiated at this hospital within 3 hours of time last known well.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS178', 1, 'Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero', '0453', null, 'Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero.', 'Patient Safety', 2, -1, false),
('CMS178', 2, 'Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero', '0453', null, 'Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero.', 'Patient Safety', 2, -1, false),
('CMS178', 3, 'Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero', '0453', null, 'Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero.', 'Patient Safety', 2, -1, false),
('CMS178', 4, 'Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero', '0453', null, 'Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero.', 'Patient Safety', 2, -1, false),
('CMS178', 5, 'Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero', '0453', null, 'Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero.', 'Patient Safety', 2, -1, false),
('CMS178', 6, 'Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero', '0453', null, 'Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero.', 'Patient Safety', 2, -1, false),
('CMS32', 1, 'Median Time from ED Arrival to ED Departure for Discharged ED Patients', '0496', null, 'Median elapsed time from emergency department arrival to emergency room departure for patients discharged from the emergency department.', 'Care Coordination', 2, -1, false),
('CMS32', 2, 'Median Time from ED Arrival to ED Departure for Discharged ED Patients', '0496', null, 'Median elapsed time from emergency department arrival to emergency room departure for patients discharged from the emergency department.', 'Care Coordination', 2, -1, false),
('CMS32', 3, 'Median Time from ED Arrival to ED Departure for Discharged ED Patients', '0496', null, 'Median elapsed time from emergency department arrival to emergency room departure for patients discharged from the emergency department.', 'Care Coordination', 2, -1, false),
('CMS32', 4, 'Median Time from ED Arrival to ED Departure for Discharged ED Patients', '0496', null, 'Median elapsed time from emergency department arrival to emergency room departure for patients discharged from the emergency department.', 'Care Coordination', 2, -1, false),
('CMS32', 5, 'Median Time from ED Arrival to ED Departure for Discharged ED Patients', '0496', null, 'Median elapsed time from emergency department arrival to emergency room departure for patients discharged from the emergency department.', 'Care Coordination', 2, -1, false),
('CMS32', 6, 'Median Time from ED Arrival to ED Departure for Discharged ED Patients', '0496', null, 'Median elapsed time from emergency department arrival to emergency room departure for patients discharged from the emergency department.', 'Care Coordination', 2, -1, false),
('CMS171', 1, 'Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision', '0527', null, 'Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within two hours prior to surgical incision. Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics within two hours prior to incision time.', 'Patient Safety', 2, -1, false),
('CMS171', 2, 'Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision', '0527', null, 'Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within two hours prior to surgical incision. Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics within two hours prior to incision time.', 'Patient Safety', 2, -1, false),
('CMS171', 3, 'Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision', '0527', null, 'Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within two hours prior to surgical incision. Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics within two hours prior to incision time.', 'Patient Safety', 2, -1, false),
('CMS171', 4, 'Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision', '0527', null, 'Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within two hours prior to surgical incision. Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics within two hours prior to incision time.', 'Patient Safety', 2, -1, false),
('CMS171', 5, 'Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision', '0527', null, 'Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within two hours prior to surgical incision. Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics within two hours prior to incision time.', 'Patient Safety', 2, -1, false),
('CMS171', 6, 'Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision', '0527', null, 'Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within two hours prior to surgical incision. Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics within two hours prior to incision time.', 'Patient Safety', 2, -1, false),
('CMS172', 1, 'Prophylactic Antibiotic Selection for Surgical Patients', '0528', null, 'Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS172', 2, 'Prophylactic Antibiotic Selection for Surgical Patients', '0528', null, 'Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS172', 3, 'Prophylactic Antibiotic Selection for Surgical Patients', '0528', null, 'Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS172', 4, 'Prophylactic Antibiotic Selection for Surgical Patients', '0528', null, 'Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS172', 5, 'Prophylactic Antibiotic Selection for Surgical Patients', '0528', null, 'Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS172', 6, 'Prophylactic Antibiotic Selection for Surgical Patients', '0528', null, 'Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS30', 1, 'Statin Prescribed at Discharge', '0639', null, 'Acute myocardial infarction (AMI) patients who are prescribed a statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS30', 2, 'Statin Prescribed at Discharge', '0639', null, 'Acute myocardial infarction (AMI) patients who are prescribed a statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS30', 3, 'Statin Prescribed at Discharge', '0639', null, 'Acute myocardial infarction (AMI) patients who are prescribed a statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS30', 4, 'Statin Prescribed at Discharge', '0639', null, 'Acute myocardial infarction (AMI) patients who are prescribed a statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS30', 5, 'Statin Prescribed at Discharge', '0639', null, 'Acute myocardial infarction (AMI) patients who are prescribed a statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS30', 6, 'Statin Prescribed at Discharge', '0639', null, 'Acute myocardial infarction (AMI) patients who are prescribed a statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS82', 5, 'Maternal Depression Screening', 'N/A', '372', 'The percentage of children who turned 6 months of age during the measurement year, who had a face-to-face visit between the clinician and the child during child''s first 6 months, and who had a maternal depression screening for the mother at least once between 0 and 6 months of life', 'Population/Public Health.', 1, -1, false),
('CMS26', 5, 'Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver', 'N/A', null, 'An assessment that there is documentation in the medical record that a Home Management Plan of Care (HMPC) document was given to the pediatric asthma patient/caregiver.', 'Patient and Family Engagement', 2, -1, false),
('CMS146', 6, 'Appropriate Testing for Children with Pharyngitis', 'N/A', '066', 'Percentage of children 3-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode.', 'Efficient Use of Healthcare Resources', 1, -1, false),
('CMS137', 6, 'Initiation and Engagement of Alcohol and Other Drug Dependence Treatment', '0004', '305', 'Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported.  Percentage of patients who initiated treatment within 14 days of the diagnosis.  Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS165', 6, 'Controlling High Blood Pressure', '0018', '236 GPRO HTN-2', 'Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS156', 6, 'Use of High-Risk Medications in the Elderly', '0022', '238', 'Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported.  Percentage of patients who were ordered at least one high-risk medication.  Percentage of patients who were ordered at least two different high-risk medications.', 'Patient Safety.', 1, -1, false),
('CMS155', 6, 'Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents', '0024', '239', 'Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are reported.  Percentage of patients with height, weight, and body mass index (BMI) percentile documentation  Percentage of patients with counseling for nutrition  Percentage of patients with counseling for physical activity', 'Population/Public Health.', 1, -1, false),
('CMS138', 6, 'Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention', '0028', '226 GPRO PREV-10', 'Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user', 'Population/Public Health.', 1, -1, false),
('CMS124', 6, 'Cervical Cancer Screening', '0032', '309', 'Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria: Women age 21-64 who had cervical cytology performed every 3 years  Women age 30-64 who had cervical cytology/human papillomavirus (HPV) cotesting performed every 5 years.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS153', 6, 'Chlamydia Screening for Women', '0033', '310', 'Percentage of women 16- 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period.', 'Population/Public Health.', 1, -1, false),
('CMS130', 6, 'Colorectal Cancer Screening', '0034', '113 GPRO PREV-6', 'Percentage of adults 50- 75 years of age who had appropriate screening for colorectal cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS126', 6, 'Use of Appropriate Medications for Asthma', 'N/A', '311', 'Percentage of patients 5- 64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS117', 6, 'Childhood Immunization Status', '0038', '240', 'Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.', 'Population/Public Health.', 1, -1, false),
('CMS127', 6, 'Pneumococcal Vaccination Status for Older Adults', '0043', '111 GPRO PREV-8', 'Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS131', 6, 'Diabetes: Eye Exam', '0055', '117 GPRO DM-7', 'Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior to the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS123', 6, 'Diabetes: Foot Exam', '0056', '163', 'The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a foot exam (visual inspection and sensory exam with mono filament and a pulse exam) during the measurement year.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS122', 6, 'Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)', '0059', '001 GPRO DM-2', 'Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.', 'Population/Public Health.', 1, -1, false),
('CMS148', 6, 'Hemoglobin A1c Test for Pediatric Patients', 'N/A', '365', 'Percentage of patients 5-17 years of age with diabetes with a Hemoglobin A1c (HbA1c) test during the measurement period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS134', 6, 'Diabetes: Medical Attention for Nephropathy', '0062', '119', 'The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS164', 6, 'Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet', '0068', '204 GPRO IVD-2', 'Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antiplatelet during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS154', 6, 'Appropriate Treatment for Children with Upper Respiratory Infection (URI)', '0069', '065', 'Percentage of children 3 months-18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS145', 6, 'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)', 'N/A', '007', 'Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS144', 6, 'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '2908', '008 GPRO HF-6', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS143', 6, 'Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation', '0086', '012', 'Percentage of patients aged 18 years and older with a diagnosis of primary openangle glaucoma (POAG) who have an optic nerve head evaluation during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS167', 6, 'Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy', '0088', '018', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS142', 6, 'Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care', '0089', '019', 'Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS139', 6, 'Falls: Screening for Future Fall Risk', '0101', '318 GPRO CARE-2', 'Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.', 'Patient Safety', 1, -1, false),
('CMS161', 6, 'Adult Major Depressive Disorder (MDD): Suicide Risk Assessment', '0104', '107', 'Percentage of patients aged 18 years and older with a diagnosis of major depressive disorder (MDD) with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS128', 6, 'Anti-depressant Medication Management', '0105', '009', 'Percentage of patients 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment. Two rates are reported.  Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks).  Percentage of patients who remained on an antidepressant medication for at least 180 days (6 months).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS157', 6, 'Oncology: Medical and Radiation - Pain Intensity Quantified', '0384', '143', 'Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified', 'Patient and Family Engagement.', 1, -1, false),
('CMS140', 6, 'Breast Cancer: Hormonal Therapy for Stage I (T1b)-IIIC Estrogen Receptor/ Progesterone Receptor (ER/PR) Positive Breast Cancer', '0387', '071', 'Percentage of female patients aged 18 years and older with Stage I (T1b) through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS52', 6, 'HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis', '0405', '160', 'Percentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS68', 7, 'Documentation of Current Medications in the Medical Record', '0419', '130 GPRO CARE-3', 'Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND  must contain the medications'' name, dosage, frequency and route of administration.', 'Patient Safety', 1, -1, false),
('CMS68', 6, 'Documentation of Current Medications in the Medical Record', '0419', '130 GPRO CARE-3', 'Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-thecounters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND  must contain the medications'' name, dosage, frequency and route of administration.', 'Patient Safety', 1, -1, false),
('CMS69', 6, 'Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan', '0421', '128 GPRO PREV-9', 'Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter.   Normal Parameters:  Age 18 years and older BMI => 18.5 and < 25 kg/m2', 'Population/Public Health.', 1, -1, false),
('CMS132', 6, 'Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures', '0564', '192', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence', 'Patient Safety', 1, -1, false),
('CMS133', 6, 'Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery', '0565', '191', 'Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had bestcorrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS159', 6, 'Depression Remission at Twelve Months', '0710', '370 GPRO MH-1', 'Patients age 18 and older with major depression or dysthymia and an initial Patient Health Questionnaire (PHQ-9) score greater than nine who demonstrate remission at twelve months (+/- 30 days after an index visit) defined as a PHQ-9 score less than 5. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS160', 6, 'Depression Utilization of the PHQ-9 Tool', '0712', '371', 'Patients age 18 and older with the diagnosis of major depression or dysthymia who have a Patient Health Questionnaire (PHQ-9) tool administered at least once during a 4-month period in which there was a qualifying visit', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS177', 6, 'Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment', '1365', '382', 'Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk', 'Patient Safety', 1, -1, false),
('CMS125', 6, 'Breast Cancer Screening', '2372', '112 GPRO PREV-5', 'Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS163', 6, 'Diabetes: Low Density Lipoprotein (LDL-C) Control (< 100 mg/dL)', 'N/A', '002', 'Percentage of patients 18-75 years of age with diabetes whose LDL-C was adequately controlled (<100 mg/dL) during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS169', 6, 'Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use', 'N/A', '367', 'Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS62', 6, 'HIV/AIDS: Medical Visit', 'N/A', '368', 'Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year with a minimum of 90 days between each visit', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS75', 6, 'Children Who Have Dental Decay or Cavities', 'N/A', '378', 'Percentage of children, age 0-20 years, who have had tooth decay or cavities during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS149', 6, 'Dementia: Cognitive Assessment', 'N/A', '281', 'Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12  month period', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS50', 6, 'Closing the Referral Loop: Receipt of Specialist Report', 'N/A', '374', 'Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.', 'Care Coordination.', 1, -1, false),
('CMS66', 6, 'Functional Status Assessment for Knee Replacement', 'N/A', '375', 'Percentage of patients aged 18 years and older with primary total knee arthroplasty (TKA) who completed baseline and follow-up patient-reported functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS56', 6, 'Functional Status Assessment for Total Hip Replacement', 'N/A', '376', 'Percentage of patients aged 18 years and older with primary total hip arthroplasty (THA) who completed baseline and follow-up patient-reported functional status assessments.', 'Patient and Family Engagement.', 1, -1, false),
('CMS179', 6, 'ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range', 'N/A', '380', 'Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the measurement period.', 'Patient Safety.', 1, -1, false),
('CMS22', 6, 'Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented', 'N/A', '317 GPRO PREV-11', 'Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated', 'Population/Public Health.', 1, -1, false),
('CMS77', 6, 'HIV/AIDS: RNA control for Patients with HIV', 'N/A', '381', 'Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit, whose most recent HIV RNA level is <200 copies/mL.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS158', 6, 'Pregnant women that had HBsAg testing', 'N/A', '369', 'This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS166', 7, 'Use of Imaging Studies for Low Back Pain', '0052', '312', 'Percentage of patients 18-50 years of age with a diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS136', 7, 'ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication', '0108', '366', 'Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.  Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.  Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS2', 7, 'Preventive Care and Screening: Screening for Depression and Follow-Up Plan', '0418', '134 GPRO PREV-12', 'Percentage of patients aged 12 years and older screened for depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen.', 'Population/Public Health.', 1, -1, false),
('CMS90', 7, 'Functional Status Assessment for Congestive Heart Failure', 'N/A', '377', 'Percentage of patients aged 65 years and older with congestive heart failure who completed initial and follow-up patient-reported functional status assessments', 'Patient and Family Engagement.', 1, -1, false),
('CMS147', 7, 'Preventive Care and Screening: Influenza Immunization', '0041', '110 GPRO PREV-7', 'Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization', 'Population/Public Health.', 1, -1, false),
('CMS135', 6, 'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)', '2907', '005', 'Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS182', 7, 'Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL-C Control (<100 mg/dL)', 'N/A', '241', 'Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had a complete lipid profile performed during the measurement period and whose most recent Low-density Lipoprotein (LDL-C) was adequately controlled (< 100 mg/dL).', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS31', 6, 'Hearing Screening Prior To Hospital Discharge', '1354', null, 'This measure assesses the proportion of births that have been screened for hearing loss before hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS100', 6, 'Aspirin Prescribed at Discharge', '0142', null, 'Acute myocardial infarction (AMI) patients prescribed aspirin at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS53', 6, 'Primary PCI Received Within 90 Minutes of Hospital Arrival', '0163', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving primary PCI during the hospital stay with a time from hospital arrival to PCI of 90 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS60', 6, 'Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival', 'N/A', null, 'Acute myocardial infarction (AMI) patients with ST-segment elevation on the ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 minutes or less.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS108', 6, 'Venous Thromboembolism Prophylaxis', '0371', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.', 'Patient Safety', 2, -1, false),
('CMS190', 6, 'Intensive Care Unit Venous Thromboembolism Prophylaxis', '0372', null, 'This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).', 'Patient Safety', 2, -1, false),
('CMS73', 6, 'Venous Thromboembolism Patients with Anticoagulation Overlap Therapy', '0373', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they should be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications or have a reason for discontinuation of overlap therapy', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS104', 6, 'Discharged on Antithrombotic Therapy', '0435', null, 'Ischemic stroke patients prescribed antithrombotic therapy at hospital discharge', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS72', 6, 'Antithrombotic Therapy By End of Hospital Day 2', '0438', null, 'Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS105', 6, 'Discharged on Statin Medication', '0439', null, 'Ischemic stroke patients who are prescribed statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS102', 6, 'Assessed for Rehabilitation', '0441', null, 'Ischemic or hemorrhagic stroke patients who were assessed for rehabilitation services.', 'Care Coordination', 2, -1, false),
('CMS113', 6, 'Elective Delivery', '0469', null, 'Patients with elective vaginal deliveries or elective cesarean births at >= 37 and < 39 weeks of gestation completed', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS9', 6, 'Exclusive Breast Milk Feeding', '0480', null, 'Exclusive breast milk feeding during the newborn''s entire hospitalization.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS55', 6, 'Median Time from ED Arrival to ED Departure for Admitted ED Patients', '0495', null, 'Median time from emergency department admission to time of discharge from the emergency room for patients admitted to the facility from the emergency department.', 'Patient and Family Engagement', 2, -1, false),
('CMS111', 6, 'Median Admit Decision Time to ED Departure Time for Admitted Patients', '0497', null, 'Median time (in minutes) from admit decision time to time of discharge from the emergency department for emergency department patients admitted to inpatient status.', 'Patient and Family Engagement', 2, -1, false),
('CMS185', 6, 'Healthy Term Newborn', '0716', null, 'Percent of term singleton live births (excluding those with diagnoses originating in the fetal period) who DO NOT have significant complications during birth or the nursery care', 'Patient Safety', 2, -1, false),
('CMS107', 6, 'Stroke Education', 'N/A', null, 'Ischemic or hemorrhagic stroke patients or their caregivers who were given educational materials during the hospital stay addressing all of the following: activation of emergency medical system, need for follow-up after discharge, medications prescribed at discharge, risk factors for stroke, and warning signs and symptoms of stroke.', 'Patient and Family Engagement', 2, -1, false),
('CMS109', 6, 'Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram or protocol.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS110', 6, 'Venous Thromboembolism Discharge Instructions', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE that are discharged to home, home care, court/law enforcement or home on hospice care on warfarin with written discharge instructions that address all four criteria: compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/ interactions.', 'Patient and Family Engagement', 2, -1, false),
('CMS114', 6, 'Incidence of Potentially-Preventable Venous Thromboembolism', 'N/A', null, 'This measure assesses the number of patients diagnosed with confirmed VTE during hospitalization (not present at admission) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date.', 'Patient Safety', 2, -1, false),
('CMS141', 7, 'Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients', '0385', '072', 'Percentage of patients aged 18 through 80 years with AJCC Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS129', 7, 'Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients', '0389', '102', 'Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer', 'Efficient Use of Healthcare Resources.', 1, -1, false),
('CMS74', 7, 'Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists', 'N/A', '379', 'Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS61', 7, 'Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed', 'N/A', '316', 'Percentage of patients aged 20 through 79 years whose risk factors have been assessed and a fasting LDL-C test has been performed.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS64', 7, 'Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDL-C)', 'N/A', '316', 'Percentage of patients aged 20 through 79 years who had a fasting LDL-C test performed and whose risk stratified fasting LDL-C is at or below the recommended LDL-C goal.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS65', 7, 'Hypertension: Improvement in Blood Pressure', 'N/A', '373', 'Percentage of patients aged 18-85 years of age with a diagnosis of hypertension whose blood pressure improved during the measurement period.', 'Clinical Process/ Effectiveness.', 1, -1, false),
('CMS188', 7, 'Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients', '0147', null, '(PN-6) Immunocompetent patients with Community-Acquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines. (Population 1) Immunocompetent ICU patients with Community-Acquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines. (Population 2) Immunocompetent non-Intensive Care Unit (ICU) patients with Community-Acquired Pneumonia who receive an initial antibiotic regimen during the first 24 hours that is consistent with current guidelines', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS71', 7, 'Anticoagulation Therapy for Atrial Fibrillation/Flutter', '0436', null, 'Ischemic stroke patients with atrial fibrillation/ flutter who are prescribed anticoagulation therapy at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS91', 7, 'Thrombolytic Therapy', '0437', null, 'Acute ischemic stroke patients who arrive at this hospital within 2 hours of time last known well and for whom t-PA was initiated at this hospital within 3 hours of time last known well.', 'Clinical Process/ Effectiveness', 2, -1, false),
('CMS178', 7, 'Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero', 'N/A', null, 'Number of surgical patients whose urinary catheter is removed on Postoperative Day 1 (POD) 1 or Postoperative Day (POD) 2 with day of surgery being day zero.', 'Patient Safety', 2, -1, false),
('CMS32', 7, 'Median Time from ED Arrival to ED Departure for Discharged ED Patients', '0496', null, 'Median elapsed time from emergency department arrival to emergency room departure for patients discharged from the emergency department.', 'Care Coordination', 2, -1, false),
('CMS171', 7, 'Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision', '0527', null, 'Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical incision. Patients who received vancomycin or a fluoroquinolone for prophylactic antibiotics should have the antibiotics initiated within two hours prior to surgical incision. Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics within two hours prior to incision time.', 'Patient Safety', 2, -1, false),
('CMS172', 7, 'Prophylactic Antibiotic Selection for Surgical Patients', '0528', null, 'Surgical patients who received prophylactic antibiotics consistent with current guidelines (specific to each type of surgical procedure).', 'Efficient Use of Healthcare Resources', 2, -1, false),
('CMS30', 7, 'Statin Prescribed at Discharge', 'N/A', null, 'Acute myocardial infarction (AMI) patients who are prescribed a statin medication at hospital discharge.', 'Clinical Process/ Effectiveness', 2, -1, false);

INSERT INTO openchpl.ucd_process(name, last_modified_user) VALUES
('ISO 9241-11', -1),
('ISO 9241-10', -1),
('ISO 13407', -1),
('ISO 16982', -1),
('ISO/IEC 62366', -1),
('NISTIR 7741', -1);
-- same for 2014 and 2015

INSERT INTO openchpl.test_tool(name, last_modified_user) VALUES
('ePrescribing Validation Tool', -1),
('HL7 CDA Cancer Registry Reporting Validation Tool', -1),
('HL7 v2 Electronic Laboratory Reporting (ELR) Validation Tool', -1),
('HL7 v2 Immunization Information System (IIS) Reporting Validation Tool', -1),
('HL7 v2 Laboratory Results Interface (LRI) Validation Tool', -1),
('HL7 v2 Syndromic Surveillance Reporting Validation Tool', -1),
('Transport Testing Tool', -1),
('Cypress', -1),
('Direct Certificate Discovery Tool', -1),
-- 2014
('HL7v2 Immunization Test Suite', -1),
('HL7v2 Syndromic Surveillance Test Suite', -1),
('HL7v2 Electronic Laboratory Reporting Validation Tool', -1),
('Electronic Prescribing', -1),
('HL7 CDA National Health Care Surveys Validator', -1),
('Transport Test Tool', -1),
('Edge Test Tool', -1),
('2015 Direct Certificate Discovery Tool', -1),
--2015
('N/A', -1),
    ('', -1);
-- Faking 'not required'; remove after Validator changed

INSERT INTO openchpl.test_standard(number, name, last_modified_user) VALUES
('170.202(a)','DIRECT: Applicability Statement for Secure Health Transport, Version 1.1, July 10, 2012', -1),
('170.202(b)','XDR and XDM for Direct Messaging Specification, Version 1, March 9, 2011', -1),
('170.202(c)','Transport and Security Specification, Version 1.0, June 19, 2012', -1),
('170.202(d)','Implementation Guide for Direct Edge Protocols, Version 1.1, June 25, 2014', -1),
('170.204(a)','Web Content Accessibility Guidelines (WCAG) 2.0, December 11, 2008', -1),
('170.204(b)','HL7 Version 3 Standard: Context-Aware Retrieval Application (Infobutton); Release 1, July 2010', -1),
('170.204(b)(1)','HL7 Version 3 Implementation Guide: URL-Based Implementations of the Context-Aware Information Retrieval (Infobutton) Domain, Release 3, December 2010', -1),
('170.204(b)(2)','HL7 Version 3 Implementation Guide: Context-Aware Knowledge Retrieval (Infobutton) Service-Oriented Architecture Implementation Guide, Release 1, HL7 Draft Standard for Trial Use, March 2011', -1),
('170.204(c)','Data Element Catalog, Version 1.1 October 2012', -1),
('170.205(a)(1)','HITSP Summary Documents Using HL7 Continuity of Care Document (CCD) Component, HITSP/C32, July 8, 2009, Version 2.5', -1),
('170.205(a)(1)','Health Level Seven Implementation Guide: Clinical Document Architecture (CDA) Release 2Continuity of Care Document (CCD), April 01, 2007', -1),
('170.205(a)(2)','ASTM E236905: Standard Specification for Continuity of Care Record (CCR), year of adoption 2005, ASTM approved July 17, 2006', -1),
('170.205(a)(2)','ASTM E236905 (Adjunct to E2369): Standard Specification Continuity of Care Record,Final Version 1.0 (V1.0), November 7, 2005', -1),
('170.205(a)(3)','HL7 Implementation Guide for CDA Release 2: IHE Health Story Consolidation, DSTU Release 1.1 (US Realm) Draft Standard for Trial Use July 2012', -1),
('170.205(b)(2)','SCRIPT Standard, Implementation Guide, Version 10.6, October, 2008, (Approval date for ANSI: November 12, 2008)', -1),
('170.205(d)(3)','PHIN Messaging Guide for Syndromic Surveillance: Emergency Department and Urgent Care Data, ADT Messages A01, A03, A04, and A08, HL7 Version 2.5.1 (Version 2.3.1 Compatible), Release 1.1, August 2012', -1),
('170.205(d)(3)','Conformance Clarification for EHR Certification of Electronic Syndromic Surveillance, ADT MESSAGES A01, A03, A04, and A08, HL7 Version 2.5.1, Addendum to PHIN Messaging Guide for Syndromic Surveillance: Emergency Department and Urgent Care Data (Release 1.1), August 2012', -1),
('170.205(d)(3)','Health Level Seven Messaging Standard Version 2.5.1 (HL7 2.5.1), An Application Protocol for Electronic Data Exchange in Healthcare Environments, February 21, 2007', -1),
('170.205(e)(3)','HL7 2.5.1 Implementation Guide for Immunization Messaging, Release 1.4, August 1, 2012', -1),
('170.205(e)(3)','Health Level Seven Messaging Standard Version 2.5.1 (HL7 2.5.1), An Application Protocol for Electronic Data Exchange in Healthcare Environments, February 21, 2007', -1),
('170.205(g)','HL7 v2.5.1 IG: Electronic Laboratory Reporting to Public Health (US Realm), Release 1 Errata and Clarifications, September, 29, 2011', -1),
('170.205(g)(3)','ELR 2.5.1 Clarification Document for EHR Technology Certification, July 16, 2012', -1),
('170.205(g)(3)','Health Level Seven Messaging Standard Version 2.5.1 (HL7 2.5.1), An Application Protocol for Electronic Data Exchange in Healthcare Environments, February 21, 2007', -1),
('170.205(g)(3)','HL7 Version 2.5.1 Implementation Guide: Electronic Laboratory Reporting to Public Health, Release 1 (US Realm) HL7 Version 2.5.1: ORU^R01, HL7 Informative Document, February, 2010', -1),
('170.205(h)','HL7 Implementation Guide for CDA Release 2: Quality Reporting Document Architecture, DTSU Release 2 (Universal Realm), Draft Standard for Trial Use, July 2012', -1),
('170.205(i)','Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries, HL7 Clinical Document Architecture (CDA), Release 1.0, August 2012', -1),
('170.205(i)','HL7 Clinical Document Architecture, Release 2.0, Normative Edition, May 2005', -1),
('170.205(j)','HL7 Version 2.5.1 Implementation Guide: S&I Framework Lab Results Interface, Release 1 - US Realm [HL7 Version 2.5.1: ORU^R01] Draft Standard for Trial Use, July 2012', -1),
('170.205(k)','HL7 Implementation Guide for CDA Release 2: Quality Reporting Document ArchitectureCategory III, DSTU Release 1 (US Realm) Draft Standard for Trial Use, November 2012', -1),
('170.207(a)(3)','International Health Terminology Standards Development Organisation (IHTSDO) Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) International Release July 31, 2012', -1),
('170.207(a)(3)','US Extension to SNOMED CT March 2012 Release', -1),
('170.207(b)(2)','CPT-4', -1),
('170.207(b)(2)','HCPCS', -1),
('170.207(b)(3)','CDT', -1),
('170.207(b)(4)','ICD-10-PCS', -1),
('170.207(c)(2)','Logical Observation Identifiers Names and Codes (LOINC) Database version 2.40,Released June 2012', -1),
('170.207(d)(2)','RxNorm, August 6, 2012 Full Release Update', -1),
('170.207(e)(2)','IIS: HL7 Standard Code Set CVX -- Vaccines Administered, updates through July 11, 2012', -1),
('170.207(f)','OMB standards for Maintaining, Collecting, and Presenting Federal Data on Race and Ethnicity, Statistical Policy Directive No. 15, Oct 30, 1997', -1),
('170.207(g)','ISO 639-2. Codes for the Representation of Names of Languages Part 2: Alpha-3 Code, April 8, 2011', -1),
('170.207(i)','ICD-10-CM', -1),
('170.207(j)','HL7 Version 3 Standard: Clinical Genomics; Pedigree, Release 1, Edition 2011, March 2012', -1),
('170.210(a)(1)','Annex A: Approved Security Functions for FIPS PUB 140-2, Security Requirements for Cryptographic Modules, Draft, May 30, 2012', -1),
('170.210(f)','Annex A: Approved Security Functions for FIPS PUB 140-2, Security Requirements for Cryptographic Modules, Draft, May 30, 2012', -1),
('170.210(g) NTP v3','RFC 1305: Network Time Protocol (Version 3) Specification, Implementation and Analysis, March 1992', -1),
('170.210(g) NTP v4','RFC 5905: Network Time Protocol Version 4: Protocol and Algorithms Specification, June 2010', -1),
('170.210(h)','ASTM E2147-01 (Reapproved 2009) Standard Specification for Audit and Disclosure Logs for Use in Health Information Systems, approved September 1, 2009', -1),

-- 2014

('170.207(b)(3)','CDT', -1),
('170.207(b)(2)','CPT-4', -1),
('170.210(h)','ASTM E2147 (Reapproved 2013)', -1),
('170.207(f)(2)','CDC Race and Ethnicity Code Set Version 1.0 (March 2000)', -1),
('170.207(e)(4)','National Drug Code Directory  Vaccine NDC Linker, updates through August 17, 2015', -1),
('170.207(b)(4)','ICD-10-PCS', -1),
('170.207(i)','ICD-10-CM', -1),
('170.207(r)(1)','Crosswalk: Medicare Provider/Supplier to Healthcare Provider Taxonomy (updated April 2, 2015)', -1),
('170.210(d)','Record treatment, payment, and health care operations disclosures', -1),
('170.207(n)(1)','Birth sex must be coded in accordance with HL7 Version 3 Standard, Value Sets for AdminstrativeGender and NullFlavor attributed as follows [PDF - 59 KB]:
(1) Male. M
(2) Female. F
(3) Unknown. nullFlavor UNK 1', -1),
('170.207(o)(1) - (2)','HL7 Version 3 Standard, Value Sets for AdminstrativeGender and NullFlavor attributed as follows:
* Something else, please describe. nullFlavor OTH
* Don''t know. nullFlavor UNK
* Choose not to disclose. nullFlavor ASKU
* Additional gender category or other, please specify. nullFlavor OTH
* Choose not to disclose. nullFlavor ASKU', -1),
('170.204(b)(3)','HL7 Version 3 Standard: Context Aware Knowledge Retrieval Application. ("Infobutton"), Knowledge Request, Release 2, 2014 Release
HL7 Implementation Guide: Service-Oriented Architecture Implementations of the Context-aware Knowledge Retrieval (Infobutton) Domain, Release 1, August 9, 2013', -1),
('170.204(b)(4)','HL7 Version 3 Standard: Context Aware Retrieval Application ("Infobutton"), Knowledge Request, Release 2, 2014 Release
HL7 Version 3 Implementation Guide: Context-Aware Knowledge Retrieval (Infobutton), Release 4, June 13, 2014', -1),
('170.205(p)(1)','IHE IT Infrastructure Technical Framework Volume 2b (ITI TF-2b) Transactions Part B  Sections 3.29  3.43, Revision 7.0, August 10, 2010', -1),
('170.205(a)(3)','HL7 Implementation Guide for CDARelease 2: IHE Health Story Consolidation, Release 1.1 - US Realm', -1),
('170.205(a)(4)','HL7 Implementation Guide for CDARelease 2: Consolidated CDA Templates for Clinical Notes (US Realm) Draft Standard for Trial Use, Volume 1  Introductory Material, Release 2.1, August 2015
HL7 Implementation Guide for CDA Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use, Volume 2  Templates and Supporting Material, Release 2.1, August 2015', -1),
('170.205(o)(1)','HL7 Version 3 Implementation Guide: Data Segmentation for Privacy (DS4P), Release 1, Part 1: CDA R2 and Privacy Metadata Reusable Content Profile, May 16, 2014', -1),
('170.205(h)(2)','HL7 CDARelease 2 Implementation Guide: Quality Reporting Document Architecture  Category I(QRDA I); Release 1, DTSU Release 3 (US Realm), Volume 1  Introductory Material, June 2015
HL7 CDARelease 2 Implementation Guide: Quality Reporting Document Architecture  Category I (QRDA I); Release 1, DSTU Release 3 (US Realm), Volume 2  Templates and Supporting Material, June 2015', -1),
('170.205(k)(1)','Quality Reporting Document Architecture Category III, Implementation Guide for CDA Release 2', -1),
('170.205(k)(2)','Errata to the HL7 Implementation Guide for CDARelease 2: Quality Reporting Document ArchitectureCategory III, DSTU Release 1 (US Realm), September 2014', -1),
('170.205(e)(4)','HL7 2.5.1 Implementation Guide for Immunization Messaging Release 1.5, October 1, 2014
HL7 2.5.1 Implementation Guide for Immunization Messaging, Release 1.5 - Addendum, July 2015', -1),
('170.207(e)(3)','HL7 Standard Code Set CVXVaccines Administered, updates through August 17, 2015', -1),
('170.205(d)(4)','PHIN Messaging Guide for Syndromic Surveillance: Emergency Department, Urgent Care, Inpatient and Ambulatory Care Settings, Release 2.0, April 21, 2015
Erratum to the CDC PHIN 2.0 Implementation Guide, August 2015; Erratum to the CDC PHIN 2.0 Messaging Guide, April 2015 Release for Syndromic Surveillance: Emergency Department, Urgent Care, Inpatient and Ambulatory Care Settings', -1),
('170.205(g)','HL7 Version 2.5.1 Implementation Guide: Electronic Laboratory Reporting to Public Health, Release 1 (US Realm)
ELR 2.5.1 Clarification Document for EHR Technology Certification V1.1', -1),
('170.205(i)(2)','HL7 Implementation Guide for CDARelease 2 Implementation Guide: Reporting to Public Health Cancer Registries from Ambulatory Healthcare Providers, Release 1; DSTU Release 1.1, Volume 1  Introductory Material, April 2015
HL7 CDARelease 2 Implementation Guide: Reporting to Public Health Cancer Registries from Ambulatory Healthcare Providers, Release 1; DSTU Release 1.1 (US Realm), Volume 2- Templates and Supporting Material, April 2015', -1),
('170.205(r)(1)','HL7 Implementation Guide for CDARelease 2  Level 3: Healthcare Associated Infection Reports, Release 1 - U.S. Realm, August 9, 2013', -1),
('170.205(s)(1)','HL7 Implementation Guide for CDA Release 2: National Health Care Surveys (NHCS), Release 1  US Realm, HL7 Draft Standard for Trial Use, Volume 1- Introductory Material, December 2014
HL7 Implementation Guide for CDARelease 2: National Health Care Surveys (NHCS), Release 1  US Realm, HL7 Draft Standard for Trial Use, Volume 2  Templates and Supporting Material, December 2014', -1),
('170.207(q)(1)','ITU-TE.123, Series E: Overall Network Operation, Telephone Service, Service Operation and Human Factors, International operation  General provisions concerning users: Notation for national and international telephone numbers, e-mail addresses and web addresses, February 2001
ITU-T E. 164, Series E: Overall Network Operation, Telephone Service, Service Operation and Human Factors, International Operation - Numbering plan of the international telephone service: The international public telecommunication numbering plan, November 2010', -1),
('170.210(g)','Request for Comments (RFC) 5905:Network Time Protocol Version 4: Protocol and Algorithms Specification, June 2010', -1),
('170.207(g)(2)','Request for Comments (RFC) 5646, "Tags for Identifying Languages," September 2009, copyright 2009', -1),
('170.205(b)(2)','SCRIPT Standard, Version 10.6, October, 2008', -1),
('170.210(a)(2)','Annex A: Federal Information Processing Standards (FIPS) Publication 140-2, Security Requirements for Cryptographic Modules, October 8, 2014', -1),
('170.210(c)(2)','FIPS PUB 180-4, Secure Hash Standard, 180-4 (August 2015)', -1),
('170.207(f)(1)','The Office of Management and Budget Standards for Maintaining, Collecting, and Presenting Federal Data on Race and Ethnicity, Statistical Policy Directive No. 15, as revised, October 30, 1997', -1),
('170.207(s)(1)','Public Health Data Standards Consortium Source of Payment Typology Code Set Version 5.0 (October 2011)', -1),
('170.207(c)(2)','Logical Observation Identifiers Names and Codes (LOINC) Database version 2.40', -1),
('170.207(c)(3)','Logical Observation Identifiers Names and Codes (LOINC) Database version 2.52, Released June 2015', -1),
('170.207(m)(1)','The Unified Code of Units of Measure, Revision 1.9, October 23, 2013', -1),
('170.202(a)(2)','Applicability Statement for Secure Health Transport, Version 1.2, August 2015', -1),
('170.202(b)','XDR and XDM for Direct Messaging Specification, Version 1, March 9, 2011', -1),
('170.202(d)','Implementation Guide for Direct Edge Protocols, Version 1.1, June 25, 2014', -1),
('170.202(e)(1)','Implementation Guide for Delivery Notification in Direct, Version 1.0, June 29, 2012', -1),
('170.207(a)(3)','International Health Terminology Standards Development Organisation (IHTSDO) SNOMED CTInternational Release July 2012 and US Extension to SNOMED CT March 2012 Release', -1),
('170.207(a)(4)','International Health Terminology Standards Development Organisation (IHTSDO) Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT), U.S. Edition, September 2015 Release', -1),
('170.207(h)','International Health Terminology Standards Development Organization (IHTSDO) Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) U.S. Edition, September 2015 Release', -1),
('170.207(d)(3)','RxNorm, a standardized nomenclature for clinical drugs produced by the United States National Library of Medicine, September 8, 2015 Release', -1),
('170.204(a)(1)','Web Content Accessibility Guidelines (WCAG) 2.0, Level A Conformance', -1),
('170.204(a)(2)','Web Content Accessibility Guidelines (WCAG) 2.0, Level AA Conformance', -1);
--2015

INSERT INTO openchpl.test_functionality(number, name, last_modified_user) VALUES
('(a)(4)(iii)','Optional: 170.314(a)(4)(iii) Plot and electronically display, upon request, growth charts for patients', -1),
('(b)(1)(i)(B)','Optional: 170.314(b)(1)(i)(B) Receive summary care record using the standards specified at 170.202(a) and (b) (Direct and XDM Validation)', -1),
('(b)(1)(i)(C)','Optional: 170.314(b)(1)(i)(C) Receive summary care record using the standards specified at 170.202(b) and (c) (SOAP Protocols)', -1),
('(f)(3)(i)(B)','Optional: 170.314(f)(3)(i)(B) Create syndrome-based public health surveillance information for transmission using the standard specified at 170.205(d)(3) (urgent care visit scenario)', -1),
('(f)(7)(i)','Optional: (f)(7)(i) EHR technology must be able to electronically create syndrome-based public health surveillance information for electronic transmission that contains the following data: (A) Patient demographics; (B) Provider specialty; (C) Provider address; (D) Problem list; (E) Vital signs; (F) Laboratory test values/results; (G) Procedures; (H) Medication list; and (I) Insurance', -1),
('(a)(5)(i)','Ambulatory setting: 170.314(a)(5)(i) Over multiple encounters in accordance with, at a minimum, the version of the standard specified in 170.207(a)(3)', -1),
('(a)(6)(i)','Ambulatory setting: 170.314(a)(6)(i) Over multiple encounters', -1),
('(a)(7)(i)','Ambulatory setting: 170.314(a)(7)(i) Over multiple encounters', -1),
('(a)(8)(iii)(B)(3)','Ambulatory setting: 170.314(a)(8)(iii)(B)(3) When a patients laboratory tests and values/results are incorporated pursuant to paragraph (b)(5)(i)(A)(1) of this section', -1),
('(a)(14)(vi)','Ambulatory setting: 170.314(a)(14)(vi) Patient communication preferences', -1),
('(b)(2)(i)(E)','Ambulatory setting: 170.314(b)(2)(i)(E) The reason for referral; and referring or transitioning provider''s name and office contact information', -1),
('(b)(7)(v)','Ambulatory setting: 170.314(b)(7)(v) The reason for referral; and referring or transitioning provider''s name and office contact information', -1),
('(b)(8)(iii)(E)','Ambulatory setting: 170.314(b)(8)(iii)(E) The reason for referral; and referring or transitioning provider''s name and office contact information', -1),
('(e)(1)(i)(A)(2)','Ambulatory setting: 170.314(e)(1)(i)(A)(2) Provider''s name and office contact information', -1),
('(e)(1)(i)(B)(1)(i)','Ambulatory setting: 170.314(e)(1)(i)(B)(1)(i) All of the data in the Common MU Data Set (which should be in their English (i.e., noncoded) representation if they associate with a vocabulary/code set) and the Provider''s name and office contact information', -1),
('(f)(3)(i)','Ambulatory setting: 170.314(f)(3)(i) (A) The standard specified in 170.205(d)(2). (B) Optional. The standard (and applicable implementation specifications) specified in 170.205(d)(3)', -1),
('(a)(5)(ii)','Inpatient setting: 170.314(a)(5)(ii) For the duration of an entire hospitalization in accordance with, at a minimum, the version of the standard specified in 170.207(a)(3)', -1),
('(a)(6)(ii)','Inpatient setting: 170.314(a)(6)(ii) For the duration of an entire hospitalization', -1),
('(a)(7)(ii)','Inpatient setting: 170.314(a)(7)(ii) For the duration of an entire hospitalization', -1),
('(b)(2)(i)(F)','Inpatient setting: 170.314(b)(2)(i)(F) Discharge instructions', -1),
('(b)(7)(vi)','Inpatient setting: 170.314(b)(7)(vi) Discharge Instructions', -1),
('(b)(8)(iii)(F)','Inpatient setting: 170.314(b)(8)(iii)(F) Discharge Instructions', -1),
('(e)(1)(i)(A)(3)','Inpatient setting: 170.314(e)(1)(i)(A)(3) Admission and discharge dates and locations; discharge instructions; and reason(s) for hospitalization', -1),
('(e)(1)(i)(B)(1)(ii)','Inpatient setting: 170.314(e)(1)(i)(B)(1)(ii) All of the data in the Common MU Data Set (which should be in their English (i.e., noncoded) representation if they associate with a vocabulary/code set) and the admission and discharge dates and locations; discharge instructions; and reason(s) for hospitalization', -1),
('(e)(1)(i)(B)(2)','Inpatient setting: 170.314(e)(1)(i)(B)(2) Electronically download transition of care/referral summaries that were created as a result of a transition of care (pursuant to the capability expressed in the certification criterion adopted at paragraph (b)(2) of this section)', -1),
('(e)(1)(i)(C)(2)','Inpatient setting: 170.314(e)(1)(i)(C)(2) Electronically transmit transition of care/referral summaries (as a result of a transition of care/referral) selected by the patient (or their authorized representative) in accordance with at least one of the following: (i) The standard specified in 170.202(a). (ii) Through a method that conforms to the standard specified at 170.202(d) and that leads to such summary being processed by a service that has implemented the standard specified in 170.202(a)', -1),
('(f)(3)(ii)','Inpatient setting: 170.314(f)(3)(ii)  The standard (and applicable implementation specifications) specified in 170.205(d)(3)', -1),
--2014

('(a)(4)(ii)(B)(1)','Alternative: 170.315(a)(4)(ii)(B)(1) To a specific set of identified users', -1),
('(a)(4)(ii)(B)(2)','Alternative: 170.315(a)(4)(ii)(B)(2) As a system administrative function', -1),
('(a)(10)(i)','Alternative: 170.315(a)(10)(i) Drug formulary checks. Automatically check whether a drug formulary exists for a given patient and medication', -1),
('(a)(10)(ii)','Alternative: 170.315(a)(10)(ii)  Preferred drug list checks. Automatically check whether a preferred drug list exists for a given patient and medication', -1),
('(a)(14)(iii)(A)(1)','Alternative: 170.315(a)(14)(iii)(A)(1) The "GMDN PT Name" attribute associated with the Device Identifier in the Global Unique Device Identification Database', -1),
('(a)(14)(iii)(A)(2)','Alternative: 170.315(a)(14)(iii)(A)(2) The "SNOMED CT Description" mapped to the attribute referenced in (a)(14)(iii)(1) (The "GMDN PT Name" attribute associated with the Device Identifier in the Global Unique Device Identification Database)', -1),
('(b)(1)(ii)(A)(5)(i)','Alternative: 170.315(b)(1)(ii)(A)(5)(i) Be notified of the errors produced', -1),
('(b)(1)(ii)(A)(5)(ii)','Alternative: 170.315(b)(1)(ii)(A)(5)(ii) Review the errors produced', -1),
('(b)(5)(ii)(A)(5)(i)','Alternative: 170.315(b)(5)(ii)(A)(5)(i) Be notified of the errors produced', -1),
('(b)(5)(ii)(A)(5)(ii)','Alternative: 170.315(b)(5)(ii)(A)(5)(ii) Review the errors produced', -1),
('(b)(6)(i)(B)(1)','Alternative: 170.315(b)(6)(i)(B)(1) To a specific set of identified users', -1),
('(b)(6)(i)(B)(2)','Alternative: 170.315(b)(6)(i)(B)(2) As a system administrative function', -1),
('(d)(7)(i)','Alternative: 170.315(d)(7)(i) Technology that is designed to locally store electronic health information on end-user devices must encrypt the electronic health information stored on such devices after use of the technology on those devices stops', -1),
('(d)(7)(ii)','Alternative: 170.315(d)(7)(ii) Technology is designed to prevent electronic health information from being locally stored on end-user devices after use of the technology on those devices stops', -1),
('(d)(9)(i)','Alternative: 170.315(d)(9)(i) Message-level. Encrypt and integrity protect message contents in accordance with the standards specified in  170.210(a)(2) and (c)(2)', -1),
('(d)(9)(ii)','Alternative: 170.315(d)(9)(ii) Transport-level. Use a trusted connection in accordance with the standards specified in  170.210(a)(2) and (c)(2)', -1),
('(g)(4)(i)(A)','Alternative: 170.315(g)(4)(i)(A) The QMS used is established by the Federal government or a standards developing organization', -1),
('(g)(4)(i)(B)','Alternative: 170.315(g)(4)(i)(B) The QMS used is mapped to one or more QMS established by the Federal government or standards developing organization(s)', -1),
('(g)(5)(i)','Alternative: 170.315(g)(5)(i) When a single accessibility-centered design standard or law was used for applicable capabilities, it would only need to be identified once', -1),
('(g)(5)(ii)','Alternative: 170.315(g)(5)(ii) When different accessibility-centered design standards and laws were applied to specific capabilities, each accessibility-centered design standard or law applied would need to be identified. This would include the application of an accessibility-centered design standard or law to some capabilities and none to others', -1),
('(g)(5)(iii)','Alternative: 170.315(g)(5)(iii) When no accessibility-centered design standard or law was applied to all applicable capabilities such a response is acceptable to satisfy this certification criterion', -1),
('(a)(1)(ii)','Optional: 170.315(a)(1)(ii)  Include a "reason for order" field', -1),
('(a)(2)(ii)','Optional: 170.315(a)(2)(ii) Include a "reason for order" field', -1),
('(a)(3)(ii)','Optional: 170.315(a)(3)(ii) Include a "reason for order" field', -1),
('(a)(13)(ii)','Optional: 170.315(a)(13)(ii) Request that patient-specific education resources be identified in accordance with the standard in  170.207(g)(2)', -1),
('(b)(1)(iii)(G)(1)(ii)','Optional: 170.315(b)(1)(iii)(G)(1)(ii) When the hour, minute, and second are associated with a date of birth the technology must demonstrate that the correct time zone offset is included', -1),
('(b)(3)(iii)','Optional: 170.315(b)(3)(iii) For each transaction listed in paragraph (b)(3)(i) of this section, the technology must be able to receive and transmit the reason for the prescription using the indication elements in the SIG Segment', -1),
('(b)(4)(vii)(A)(2)','Optional: 170.315(b)(4)(vii)(A)(2) When the hour, minute, and second are associated with a date of birth the technology must demonstrate that the correct time zone offset is included', -1),
('(c)(3)(ii)','Optional: 170.315(c)(3)(ii) That can be electronically accepted by CMS', -1),
('170.102(13)(ii)(C) ','Optional: Common Clinical Data Set 170.102(13)(ii)(C) The patients BMI percentile per age and sex for youth 2-20 years of age, weight for age per length and sex for children less than 3 years of age, and head occipital-frontal circumference for children less than 3 years of age must be recorded in numerical values only in accordance with the standard specified in  170.207(c)(3) and with the associated applicable unit of measure for the vital sign measurement in the standard specified in  170.207(m)(1). For BMI percentile per age and sex for youth 2-20 years of age and weight for age per length and sex for children less than 3 years of age, the reference range/scale or growth curve should be included as appropriate', -1),
('170.102(19)(i)','Optional: Common Clinical Data Set 170.102(19)(i) For certification to the 2015 Edition health IT certification criteria in accordance with the "Assessment and Plan Section (V2)" of the standard specified in  170.205(a)(4);', -1),
('170.102(19)(ii)','Optional: Common Clincial Data Set 170.102(19)(ii)  For certification to the 2015 Edition health IT certification criteria in accordance with the "Assessment Section (V2)" and "Plan of Treatment Section (V2)" of the standard specified in  170.205(a)(4). ', -1),
('(a)(6)(i)','Ambulatory: 170.315(a)(6)(i) Over multiple encounters in accordance with, at a minimum, the version of the standard specified in  170.207(a)(4)', -1),
('(a)(7)(i)','Ambulatory: 170.315(a)(7)(i) Over multiple encounters', -1),
('(a)(8)(i)','Ambulatory: 170.315(a)(8)(i) Over multiple encounters', -1),
('(b)(1)(iii)(E)','Ambulatory: 170.315(b)(1)(iii)(E) The reason for referral; and referring or transitioning provider''s name and office contact information', -1),
('(b)(4)(v)','Ambulatory: 170.315(b)(4)(v) The reason for referral; and referring or transitioning provider''s name and office contact information', -1),
('(b)(5)(i)(E) ','Ambulatory: 170.315(b)(5)(i)(E) The reason for referral; and referring or transitioning provider''s name and office contact information', -1),
('(b)(6)(ii)(E) ','Ambulatory: 170.315(b)(6)(ii)(E) The reason for referral; and referring or transitioning provider''s name and office contact information', -1),
('(e)(1)(i)(A)(2)','Ambulatory: 170.315(e)(1)(i)(A)(2) Providers name and office contact information', -1),
('(e)(1)(i)(B)(2)(i)','Ambulatory: 170.315(e)(1)(i)(B)(2)(i) All of the following data:
(1) The Common Clinical Data Set (which should be in their English (i.e., non-coded) representation if they associate with a vocabulary/code set).
(2) Ambulatory setting only. Providers name and office contact information.
(4) Laboratory test report(s). Laboratory test report(s), including:
(i) The information for a test report as specified all the data specified in 42 CFR 493.1291(c)(1) through (7);
(ii)The information related to reference intervals or normal values as specified in 42 CFR 493.1291(d); and
(iii)The information for corrected reports as specified in 42 CFR 493.1291(k)(2).
(5) Diagnostic image report(s)', -1),
('(a)(5)(ii)','Inpatient: 170.315(a)(5)(ii) Enable a user to record, change, and access the preliminary cause of death and date of death in the event of mortality', -1),
('(a)(6)(ii)','Inpatient: 170.315(a)(6)(ii) For the duration of an entire hospitalization in accordance with, at a minimum, the version of the standard specified in 170.207(a)(4)', -1),
('(a)(7)(ii)','Inpatient: 170.315(a)(7)(ii) For the duration of an entire hospitalization', -1),
('(a)(8)(ii)','Inpatient: 170.315(a)(8)(ii) For the duration of an entire hospitalization', -1),
('(b)(1)(iii)(F)','Inpatient: 170.315(b)(1)(iii)(F) Discharge Instructions', -1),
('(b)(4)(vi)','Inpatient: 170.315(b)(4)(vi) Discharge Instructions', -1),
('(b)(5)(i)(F)','Inpatient: 170.315(b)(5)(i)(F) Discharge Instructions', -1),
('(b)(6)(ii)(F)','Inpatient: 170.315(b)(6)(ii)(F) Discharge Instructions', -1),
('(e)(1)(i)(A)(3)','Inpatient: 170.315(e)(1)(i)(A)(3) Admission and discharge dates and locations; discharge instructions; and reason(s) for hospitalization', -1),
('(e)(1)(i)(B)(2)(ii)','Inpatient: 170.315(e)(1)(i)(B)(2)(ii) All of the following data:
(1) The Common Clinical Data Set (which should be in their English (i.e., non-coded) representation if they associate with a vocabulary/code set).
(3) Inpatient setting only. Admission and discharge dates and locations; discharge instructions; and reason(s) for hospitalization.
(5) Diagnostic image report(s)', -1),
('(e)(1)(i)(B)(3)','Inpatient: 170.315(e)(1)(i)(B)(3) Patients (and their authorized representatives) must be able to download transition of care/referral summaries that were created as a result of a transition of care (pursuant to the capability expressed in the certification criterion specified in paragraph (b)(1) of this section)', -1),
('(e)(1)(i)(C)(2)','Inpatient: 170.315(e)(1)(i)(C)(2)  Transmit transition of care/referral summaries (as a result of a transition of care/referral as referenced by (e)(1)(i)(B)(3)) selected by the patient (or their authorized representative) in  both of the following ways:
(i) Email transmission to any email address; and
(ii)An encrypted method of electronic transmission', -1);
--2015

INSERT INTO openchpl.accessibility_standard(name, last_modified_user) VALUES
('170.204(a)(1)', -1),
('170.204(a)(2)', -1);

INSERT INTO openchpl.qms_standard(name, last_modified_user) VALUES
('21 CFR Part 820', -1),
('ISO 9001', -1),
('ISO 14971', -1),
('ISO 13485', -1),
('IEC 62304', -1);

INSERT INTO openchpl.activity_concept (activity_concept_id, concept, last_modified_user) VALUES
(1, 'CERTIFIED_PRODUCT', -1),
(2, 'PRODUCT', -1),
(3, 'DEVELOPER', -1),
(4, 'CERTIFICATION', -1),
(5, 'CQM', -1),
(6, 'CERTIFICATION_BODY', -1),
(7, 'VERSION', -1),
(8, 'USER', -1),
(9, 'ATL', -1),
(10, 'PENDING_CERTIFIED_PRODUCT', -1),
(11, 'API_KEY', -1),
(12, 'ANNOUNCEMENT', -1),
(13, 'CERTIFICATION_ID', -1);

SET statement_timeout = 0;
SET lock_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SET check_function_bodies = false;
SET client_min_messages = warning;
SET search_path = openchpl, pg_catalog;

insert into openchpl.certification_body (name, acb_code, last_modified_user) values ('InfoGard', '02', -1), ('CCHIT', '03', -1), ('Drummond Group Inc.', '04', -1), ('SLI Global', '05', -1), ('Surescripts LLC', '06', -1), ('ICSA Labs', '07', -1), ('Pending', '08', -1);
insert into openchpl.testing_lab (name, testing_lab_code, last_modified_user) values ('InfoGard', '02', -1), ('CCHIT', '03', -1), ('Drummond Group Inc.', '04', -1), ('SLI Global', '05', -1), ('ICSA Labs', '07', -1), ('National Technical Systems', '09', -1);

INSERT INTO acl_class VALUES (1, 'gov.healthit.chpl.auth.dto.UserDTO'), (2, 'gov.healthit.chpl.dto.CertificationBodyDTO'),
							 (3, 'gov.healthit.chpl.dto.PendingCertifiedProductDTO'), (4, 'gov.healthit.chpl.dto.TestingLabDTO');
SELECT pg_catalog.setval('acl_class_id_seq', 5, true);

--inserts users that can have acls
INSERT INTO acl_sid VALUES
(-2, true, 'admin');

--insert user objects
INSERT INTO acl_object_identity VALUES
(-2, 1, -2, NULL, -2, true);

--insert acb objects
INSERT INTO acl_object_identity VALUES
(2, 2, 1, NULL, -2, true),
(3, 2, 2, NULL, -2, true),
(4, 2, 3, NULL, -2, true),
(5, 2, 4, NULL, -2, true),
(6, 2, 5, NULL, -2, true),
(7, 2, 6, NULL, -2, true),
(8, 2, 7, NULL, -2, true);

-- insert atl objects
INSERT INTO acl_object_identity VALUES
(9, 4, 1, NULL, -2, true),
(10, 4, 2, NULL, -2, true),
(11, 4, 3, NULL, -2, true),
(12, 4, 4, NULL, -2, true),
(13, 4, 5, NULL, -2, true),
(14, 4, 6, NULL, -2, true);

--insert acls for users
INSERT INTO acl_entry VALUES
(1, -2, 0, -2, 16, true, false, false);

--insert acls for acbs
INSERT INTO acl_entry VALUES
(2, 2, 0, -2, 16, true, false, false),
(3, 3, 0, -2, 16, true, false, false),
(4, 4, 0, -2, 16, true, false, false),
(5, 5, 0, -2, 16, true, false, false),
(6, 6, 0, -2, 16, true, false, false),
(7, 7, 0, -2, 16, true, false, false),
(8, 8, 0, -2, 16, true, false, false);

-- insert acls for atls
INSERT INTO acl_entry VALUES
(9, 9, 0, -2, 16, true, false, false),
(10, 10, 0, -2, 16, true, false, false),
(11, 11, 0, -2, 16, true, false, false),
(12, 12, 0, -2, 16, true, false, false), 
(13, 13, 0, -2, 16, true, false, false), 
(14, 14, 0, -2, 16, true, false, false); 

SELECT pg_catalog.setval('acl_entry_id_seq', 15, true);
SELECT pg_catalog.setval('acl_object_identity_id_seq', 15, true);
SELECT pg_catalog.setval('acl_sid_id_seq', 2, true);

--user contacts.
-- one contact for each user that's getting pre-loaded. there are 2 chpl admins and 7 acb admins
INSERT INTO contact (contact_id, first_name, last_name, email, phone_number, signature_date, last_modified_user) VALUES
(-2, 'Administrator', 'Administrator', 'info@ainq.com', '(301) 560-6999', CURRENT_DATE, -1);
SELECT pg_catalog.setval('contact_contact_id_seq', 2, true);

INSERT INTO "user" (user_id, user_name, password, compliance_signature, account_expired, account_locked, credentials_expired, account_enabled, last_modified_user, contact_id) VALUES
(-2, 'admin', '$2a$10$vVXOupd9DckGsQPtZ5h9seYCGzqYb3A35r/GNuP/rRbK2eq2KxtA2', CURRENT_DATE, false, false, false, true, -1, -2);
SELECT pg_catalog.setval('user_user_id_seq', 2, true);

INSERT INTO user_permission (user_permission_id, "name", description, authority, last_modified_user) VALUES
(-2, 'ADMIN', 'This permission confers administrative privileges to its owner.', 'ROLE_ADMIN', -1),
(1, 'USER_CREATOR' ,'This permission allows a user to create other users',	'ROLE_USER_CREATOR' , -1),
(2, 'ACB_ADMIN' ,'This permission gives a user write access to their ACBs.',	'ROLE_ACB_ADMIN' , -1),
(3, 'ACB_STAFF' ,'This permission gives a user read access to their ACBs',	'ROLE_ACB_STAFF' , -1),
(4, 'ATL_ADMIN' ,'This permission gives a user write access to their ATLs.',	'ROLE_ATL_ADMIN' , -1),
(5, 'ATL_STAFF' ,'This permission gives a user write access to their ATLs.',	'ROLE_ATL_STAFF' , -1),
(6, 'CMS_STAFF' ,'This permission gives a user read access to CMS reports.',	'ROLE_CMS_STAFF' , -1),
(7, 'ONC_STAFF' ,'This permission gives a user access to the CMS Download file and report navigation section. It denies editing of Users/Products/CPs/ACBs/etc. No user invitation ability.', 'ROLE_ONC_STAFF' , -1);

SELECT pg_catalog.setval('user_permission_user_permission_id_seq', 8, true);

INSERT INTO global_user_permission_map (user_id, user_permission_id_user_permission, last_modified_user) VALUES
(-2, -2, -1);
SELECT pg_catalog.setval('global_user_permission_map_global_user_permission_id_seq', 16, true);
